Cite this: *Nat. Prod. Rep.*, 2012, **29**, 752

www.rsc.org/npr

REVIEW

Synthetic approaches toward sesterterpenoids

Daniel T. Hog, Robert Webster and Dirk Trauner*

Received 12th January 2012
DOI: 10.1039/c2np20005h

Covering: up to December 2011

Sesterterpenoids account for many bioactive natural products, often with unusual and complex structural features, which makes them attractive targets for synthetic chemists. This review surveys efforts undertaken toward the synthesis of sesterterpenoids, focusing on completed total syntheses and covering *ca.* 50 natural products in total.

1 Introduction

Ever since Komppa's pioneering work on camphor,[1] terpenoids (*i.e.* regular terpenes and their partially degraded congeners) have played a prominent role in the development of organic synthesis. Many key concepts in organic chemistry, such as Wagner Meerwein rearrangements, Diels Alder reactions, or polyolefin cyclizations, were first explored with members of this large natural product class. As the power of organic synthesis grew, increasingly complex terpenoids have been targeted and their successful total syntheses must now number in the hundreds.

Within the terpenoid family, sesterterpenoids probably form the smallest class, comprising less than a thousand known compounds. They consist of two and a half (*sester* in Latin) terpene units, which for historic reasons were defined as pieces made of ten carbons. As such, sesterterpenoids contain 25 (or slightly fewer) carbon atoms. They have been recovered from a variety of sources, including lichens, higher plants, fungi, insects and sponges, often showing significant biological activity *e.g.* as anti inflammatory or cytotoxic agents.

With their comparatively large size, structural complexity, and molecular diversity, sesterterpenoids represent highly attractive targets for total synthesis and they have spurred many elegant synthetic approaches. These are the subject of the present review, which focuses specifically on the synthesis of sesterterpenoids rather than their isolation, structure and biological evaluation. We refer to the review series *sesterterpenoids*[2] in this journal and to similar accounts[3–5] for details on these aspects. Furthermore, we will limit our discussion to members of the class that have attracted substantial attention from the synthetic community and will largely ignore compounds where little or no synthetic work has been reported.

2 Linear sesterterpenoids

The natural products of this subclass possess a linear carbon chain, which in most cases has been partially oxidized. Such an oxygenation often leads to cyclization, resulting in furans and/or lactones. In contrast to the other sesterterpenoid subclasses, no additional C C bond is formed during biosynthesis. Although numerous linear sesterterpenoids have been reported, very few have been targeted by synthetic chemists to date.

In 1998, Romo and co workers reported the total synthesis of (+) okinonellin B (**1**) (Scheme 1).[6,7] Retrosynthetic bifurcation of

Fakultat fur Chemie und Pharmazie, Ludwig Maximilians Universitat Munchen, and Munich Center for Integrated Protein Science, Butenandtstr. 5 13, 81377 Munchen, Germany. E mail: Dirk.Trauner@lmu.de



Scheme 1 Romo's disconnection of (+) okinonellin B. Bn benzyl.

the natural product *via* Negishi coupling allowed for its assembly in a convergent manner. A β lactone **3** was employed to address the stereoselective synthesis of the highly substituted γ butyro lactone within okinonellin B (**1**). The absolute configuration of the isolated allylic stereocenter bearing a methyl group origi nated from the commercially available (*S*) Roche ester (**2**). In 2001, Norizuki and co workers[8] synthesized ( ) idiadione (**4**)[9] starting from (*S*) citronellal, establishing the single stereogenic center to be (*S*) configured (Fig. 1). Another linear fur anosesterterpenoid, (18*S*) variabilin (**5**)[10] was prepared effi ciently by Yoda *et al.* in 2004,[11] utilizing a lipase catalyzed asymmetric desymmetrization to install the sole stereocenter. Recently, Goméz and Fall accomplished the enantioselective synthesis of (+) palinurin (**6**), which was found to act as a non competitive inhibitor of GSK 3β, a kinase implicated in Alz heimer's desease.[12,13] They achieved the synthesis *via* the chiral auxiliary controlled diastereoselective alkylation of a tetronic acid derivative and a series of standard olefinations to install the double bonds with the required configurations. Similar to the synthesis of okonellin B (**1**), the isolated allylic stereogenic center bearing a methyl group was incorporated starting from the (*R*) Roche ester *ent* (**2**).

Moenocinol (**7**)[14] is an achiral sesterterpenoid alcohol isolated as a hydrolysis product of the antibiotic moenomycin A, which is produced by various *Streptomyces* strains (Fig. 1).[15] Numerous attempts to synthesize moenomycin A and its components have been reported,[16,17] including several syntheses of moenocinol (**7**) itself by the groups of Tschesche,[18] Grieco,[19] Kocienski,[20] Coates,[21] Welzel,[22] Schmidt,[23] Yang[24] and Hilt.[25] This work has already been thoroughly reviewed elsewhere,[17] and consequently will not be elaborated upon here.

3 Monocarbocyclic sesterterpenoids

3.1 Manoalide

The sesterterpenoid (+) manoalide (**8**) was first isolated, along with a number of structurally similar metabolites, in the early 1980s by de Silva and Schröder from the Pacific sponge *Luffar iella variablis* (Fig. 2).[26] Although its structure is relatively simple, bearing only one defined stereogenic center, manoalide (**8**) has attracted substantial attention from synthetic chemists. This is likely due to the fact that manoalide (**8**) is a potent and irre versible inhibitor of phospholipase A_2: the enzyme that catalyzes arachidonic acid release from membrane bound phosphogly cerides, resulting in the formation of pro inflammtory factors.[27] In 1985, Katsumara *et al.* reported the first racemic synthesis of manoalide (**8**),[28] which was followed by six further syntheses of the racemate by the groups of Garst,[29] Katsamura,[30] Kocienski[31]

From left to right : **Daniel T. Hog**, **Dirk Trauner and Robert Webster**.

Robert Webster was born in Saskatoon, Saskatchewan, Canada (1981). In 2004, he graduated from the University of Saskatch ewan with a B.Sc. in chemistry (great distinction). Opting to continue his studies at the University of Toronto, where his work focused on terpenoid total synthesis and asymmetric rhodium catalyzed reactions, he earned his Ph.D. in 2010 under the super vision of Professor Mark Lautens. He is currently an Alexander von Humboldt postdoctoral fellow exploring biomimetic natural product total synthesis in the laboratories of Professor Dirk Trauner at the LMU München.

Daniel T. Hog was born (1984) and raised in Freiburg im Breis gau, Germany, before moving to Münster to study chemistry (2004). After a research internship with Professor Antonio M. Echavarren at ICIQ, Tarragona, Spain, he conducted his Diploma research under the supervision of Professor Martin Oestreich at WWU Münster. In 2009, he joined the laboratories of Professor Dirk Trauner at LMU München as a graduate student. He is currently pursuing natural product synthesis of sesterterpenoids, supported by a scholarship from the Fonds der Chemischen Industrie.

Dirk Trauner was born in Linz, Austria. After studying biology and then biochemistry at the University of Vienna, he joined the group of Professor Johann Mulzer at the Free University of Berlin to pursue natural product synthesis. In the late 1990s, he was a postdoctoral fellow with Professor Samuel J. Danishefsky at the Memorial Sloan Kettering Cancer Center in New York City. In 2000, he joined the University of California, Berkeley, where he rose through the ranks to become an Associate Professor of Chemistry. In 2008, he moved to the University of Munich, where he currently resides as a Professor for Chemical Biology and Genetics.

and Hoffmann.[32] However, only two enantioselective routes toward manoalide (**8**) have been reported to date.

Almost twenty years after its isolation, Sodano and co workers succeeded in the first asymmetric synthesis of (+) manoalide (**8**) (Scheme 2).[33] To this end, they prepared alkyl iodide **10** starting from β ionone (**9**) and improved the yields of the sequence leading to this compound previously reported by Hoffmann.[32] Sodano *et al.* envisaged utilizing an enantioselective aldol reaction to install the single stereogenic center. Thus, subjecting 3 furaldehyde (**15**) and silyloxydiene **11** to a mixture of Ti(O*i* Pr)$_4$ and (*R*) BINOL (known as Sato's procedure) gave the corresponding aldol product (88% *ee*), which was subse quently converted into ester **12** by microwave irradiation in MeOH. This intermediate was then alkylated with homoallyl iodide **10**, requiring the presence of tetrabutylammonium salt **16** as a phase transfer catalyst to furnish, after diastereoselective ketone reduction, furan **13**. An ensuing three step protocol generated lactone **14** *via* ester hydrolysis, acetylation with concomitant lactonization and finally elimination of acetate in the presence of DBU. Having obtained the corresponding lactol by reduction with DIBAL H, Sodano *et al.* finally accessed (+) manoalide (**8**) by photooxygenation of the furan moiety.

Several years later, in 2003, Kocienski *et al.* reported the second enantioselective synthesis of (+) manaolide (**8**) (Scheme 3).[34] In contrast to Sodano's work, the single stereogenic center was installed using a Sharpless kinetic resolution. However, Kocienski opted to utilize the same homoallyl iodide **10** featured in Sodano's synthesis, that was also prepared from β ionone (**9**), but using a different eight step protocol. Their second building block was derived from furyl aldehyde **17**, which was reacted with propargyl magnesium bromide to afford racemic prop argylic alcohol **18**. Exposure of the alcohol to Sharpless asymmetric epoxidation conditions afforded the desired (*R*) configured alcohol **18** in 41% yield. Successive Mo catalyzed cycloisomerisation in the presence of Bu_3SnOTf led to vinyl stannane **19**, the required intermediate for their second key step: a Cu mediated 1,2 metalate rearrangement. For this purpose,



Fig. 1 Molecular structures of successfully synthesized linear sesterterpenoids.



Fig. 2 The molecular structure of the sesterterpenoid (+) manoalide.

exposure of stannane **19** to *s* BuLi generated the corresponding vinyl lithium species, which was then added to mixed cuprate **21** previously prepared from homoallyl iodide **10**, *t* BuLi and 1 pentynylcopper. This procedure triggered the rearrangement to form an intermediate vinyl cuprate species that was quenched with I_2 to generate vinyl iodide **20**. With this compound in hand, only three steps remained to finish the synthesis: a Pd catalyzed carbonylation yielded a lactone that was subsequently reduced by DIBAL H to the corresponding lactol. Similar to Sodano's endgame, photooxidation of the furan moiety in the presence of Rose Bengal gave rise to (+) manoalide (**8**).

Within the synthesis of (+) manoalide (**8**) Kocienski and co workers took advantage of a 1,2 metalate rearrangement, a methodology, which had been applied earlier in the same



Scheme 2 Sodano's asymmetric synthesis of (+) manoalide. TMS tri methylsilyl, BINOL 1,1′ bi(2 naphtol), Ac_2O acetic anhydride, py pyridine, DBU 1,8 diazabicyclo[5.4.0]undec 7 ene, DIBAL H diiso butylaluminum hydride.

laboratories *en route* to the related natural product luffariolide E (**26**) (Scheme 4).[35,36] The 1,2 metalate rearrangement, the same key step used in Kocienski's synthesis of manoalide (**8**), was carried out using vinyl stannane **22** and cuprate **27**. Treating stannane **22** with *n* BuLi generated the corresponding organo lithium species, which was then reacted with dialkyl cuprate **27** to form higher order cuprate **23**. The latter rearranged with inversion of the alkene geometry to yield alkenyl cuprate **24**. In contrast to their synthesis of manoalide (**8**), the sequence was not terminated by quenching with I_2, but by direct carboxylation and subsequent esterification to give the (*Z*) configured alkene **25** in an overall yield of 48%. Three further transformations gave rise to (3*R*,4*R*) luffariolide E (**26**) in racemic form, but the NMR data did not match that of the isolated natural product. Therefore, the authors concluded by chemical correlation to related natural products of known absolute configuration[35] that natural luffariolide E (**26**) possesses the (3*S*,4*R*) configuration. Moreover, Kocienski *et al.* prepared racemic (3*S*,4*R*) luffariolide E later that year, verifying their conclusion.[37]

3.2 Diumycinol

Another compound targeted within this subclass of sesterterpenoids is diumycinol (**28**) (Fig. 3).[38] In analogy to its acyclic isomer moenocinol (**7**) (Section 2), this sesterterpenoid alcohol is a hydrolysis product from moenomycin type antibiotics, more precisely from diumycin. While there was initially some controversy concerning whether these alcohols truly arise from a terpenoid origin, it has been shown that they are indeed formed *via* the non mevalonate pathway from a C_{10} and a C_{15} precursor.[39] In contrast to moenocinol (**7**), however, diumycinol (**28**) has attracted less attention from synthetic groups and only two racemic syntheses by the groups of Grieco[40] and Kocienski[41] have been reported. These findings have recently been reviewed in detail by Wenzel in an overview of syntheses dealing with the transglycosylation step in peptidoglycan biosynthesis.[17]

3.3 Ceriferic acid derivatives

A series of macrocyclic sesterterpenoids, including ceriferic acid (**29**), its methyl ester **30** and ceriferic acid I (**32**), imbued with a cembrenoid 14 membered ring, were isolated in the late 1970s from the wax secreted by the Japanese scale insect *Cerplastes ceriferus* (Fig. 4).[42] Two groups, namely Kato's and Kodama's, were responsible for the synthesis of ceriferol (**31**),[43] ceriferol I (**34**),[44] methyl ceriferate I (**33**),[44] and the deoxygenated analogue cericerene (**35**).[45] None of the above syntheses were asymmetric, so the lone stereocenter (tentatively assigned as (*R*) by Naya[42d] based on analogy to the optical rotation of related hydrocarbons) has not been unambiguously assigned.

Kato's synthetic work[43,45] in the early 1980s was instrumental for elucidating the structures of this sesterterpenoid subclass. Both ceriferol (**31**) and ceriferol I (**34**), isomers differing by the position of a double bond, were synthesized starting from geranylgeranyl acetone (**36**) (Scheme 5). The key step, a surprisingly efficient and selective Friedel Crafts type macrocyclization of acid chloride **37**, was mediated by $SnCl_4$ to close the 14 membered ring and produce β chloro ketone **38** in 97% yield. Elimination of chloride from the side chain of ketone **38** was unselective, giving a 1 : 1 mixture alkenes that were then



Scheme 3 Kocienski's asymmetric synthesis of (+) manoalide. TES triethylsilyl, DIPT diisopropyl tartrate, DIBAL H diisobutyl aluminium hydride, Bu_3SnOTf tributylstannyl trifluoromethane sulfonate.



Scheme 4 Mechanistic details of the 1,2 metalate rearrangement: the key step from Kocienski's syntheses of luffariolide E and (+) manoalide. rt room temperature, HMPA hexamethylphosphoramide.

separated, and each was carried through a sequence of synthetic manipulations to afford racemic ceriferol (**31**) and ceriferol I (**34**), respectively.

In 1986, Kodama reported a racemic synthesis of methyl cer iferate I (**33**) (Scheme 6).[44] The coupling of allyl bromide **39** and geraniol derived sulfide **43** under basic conditions furnished dioxolane **40** that was later desulfurized and deprotected to give aldehyde **41**. The side chain was appended using ester **44**, and after an eleven step protocol, including a Claisen rearrangement, the cyclization precursor, phosphonate **42**, was obtained. Treatment of phosphonate **42** with NaH in DME succeeded in Horner Wadsworth Emmons macro cyclization, but gave methyl ceriferate I (**33**) as the minor double bond isomer along with the undesired *cis* isomer as the major product (not shown).

4 Bicarbocylic sesterterpenoids

4.1 Terpestacin

The fungal metabolite terpestacin (**45**) was first isolated by Oki and co workers in 1993 and its relative configuration was unambiguously confirmed by X ray crystallography (Fig. 5).[46] Terpestacin (**45**) was shown to inhibit the formation of syncytia, *i.e.* multinuclear cell bodies, which are part of the pathology of HIV infection. This property, in addition to its interesting structural features, which include a 15 membered carbomacro cycle with three trisubstituted olefins and four stereogenic centers, was due cause for capturing the attention of several synthetic groups.[47] Successful approaches to this target prior to 2007 have been reviewed in some detail by Maimone and Baran.[48] Nevertheless, this section will present an overview of the topic that includes the additional material published since 2007.

In 1998 Tatsuta *et al.* reported a racemic synthesis,[49] and later that year the first enantioselective route to terpestacin (**45**).[50] They followed an *ex chiral pool* strategy, using tri *O* acetyl D galactal as a starting material (38 linear steps, not shown). Tatsuta's successful syntheses not only verified the structure of terpestacin, but also confirmed its absolute configuration. Since then, four additional syntheses have appeared in literature by the groups of Myers,[51] Jamison,[52] Trost[53] and Tius.[54]

The Myers group successfully completed the asymmetric total synthesis of terpestacin (**45**) in 2002 in 19 steps and an overall yield of 5.8%.[51] Their route employed a sequence of diastereo selective enolate alkylations, starting from optically pure amide **47** that was obtained *via* allylation of (*R*,*R*) pseudoephedrine propionamide, exploiting a methodology previously developed in the same laboratories (Scheme 7). Subsequent diaster eoselective iodolactonization led to δ lactone **48** with concomi tant cleavage of the chiral auxiliary. The resulting alkyl iodide was transformed into an alcohol, followed by TIPS protection to give lactone **49**, thus setting the stage for a second



Fig. 3 The structure of the sesterterpenoid alcohol diumycinol.



Fig. 4 Molecular structures of ceriferic acid and related sesterterpenoids.

diastereoselective enolate alkylation. The bulky TIPS ether was postulated to direct *si* face attack from the allylic bromide **56** to generate the desired quaternary stereocenter in lactone **50** with good fidelity (dr 8.8 : 1). Installation of the allylic iodide and cyclopentenone moiety in compound **51** required four steps and generated the requisite functionality for a third enolate alkyl ation to close the macrocycle. This reaction took place smoothly using Masamune's base in high dilution (0.002 M) and con structed the desired *trans* fused [13.3.0] bicycle **52** with accept able stereocontrol (*trans*:*cis* = 4.8 : 1). An aldol reaction with the (*Z*) ketene acetal **57**, derived from *tert* butyl propionate, intro duced the desired three carbon chain selectively from the *β* face, giving rise to alcohol **53**. Subsequent two step reduction of the ester functionality was accompanied by cleavage of the silyl enol ether and produced a hemiketal that was chemoselectively dehydrated using Martin's sulfurane. Epoxidation of the result ing cyclic enol ether **54** with DMDO and ring opening under acidic conditions yielded the presumed triol **55** as an interme diate, which collapsed *via* isomerisation and dehydration when treated with methanolic K_2CO_3. Finally, cleavage of the TBS group with 1 N HCl in THF gave rise to ( ) terpestacin (**45**).



Scheme 5 Kato's acylative macrocyclization approach to ceriferol.



Scheme 6 Kodama's racemic synthesis of methyl cerifate I. DABCO 1,4 diazabicyclo[2.2.2]octane, DME 1,2 dimethoxyethane, *p*TsOH *p* toluenesulfonic acid.



Fig. 5 Molecular structures of ( ) terpestacin and ( ) fusaproliferin. Ac acetyl.

Interestingly, despite the absolute configuration of Myers' synthetic ( ) terpestacin (**45**) matching the configuration assigned by Tatsuta in 1998, Myers' optical rotation measure ment was in disagreement with the previously reported values from both Tatsuta (synthesis) and Oki (isolation), who reported terpestacin (**45**) to be dextrorotary. Upon careful investigation, Myers *et al.* concluded that the earlier reports contained arte factually erroneous measurements caused by chloroetherification of terpestacin (**45**) initiated by $CHCl_3$, the solvent used for the optical rotation measurement. They found that prolonged exposure of ( ) terpestacin (**45**) to $CHCl_3$ formed a chlorinated product (not shown) that was dextrorotary with a larger magnitude than ( ) terpestacin (**45**) itself. Myers *et al.* dispelled the ambiguity of the stereochemical assignment and successfully synthesized ( ) fusaproliferin (**46**)[55] from ( ) terpestacin (**45**) in two additional steps by bisacetylation and mono deacetylation, verifying the assignment of its absolute configuration as well.

The following year, the third enantioselective synthesis of ( ) terpestacin (**45**) was disclosed by Jamison's group,[52] utilizing a stereoselective intermolecular reductive coupling between an alkyne and an aldehyde, a methodology that was conceived in their laboratories. In contrast to Myers' strategy, Jamison installed the three carbon side chain at the beginning of the synthesis using an NMO promoted Pauson Khand reaction between dicobalt complex **58** and enantiomerically pure dihy drofuran **59**, yielding bicycle **60** with complete control of regio and diastereoselectivity (Scheme 8). The latter was transformed into the desired alkyne **61** over a five step sequence *via* cuprate addition, reduction (both occurring from the convex face), desilylation, alkyne isomerisation and finally TMS protection of the resulting alcohol. The aldehyde fragment **63** was prepared in a straightforward manner from diol **62**, that was in turn obtained from (*E*,*E*) farnesyl acetate by chemo and enantioselective dihydroxylation. When the key aldehyde/alkyne coupling step was attempted using $Ni(cod)_2$ with Et_3B and Bu_3P, the reaction exhibited low regioselectivty (1.5 : 1) and no diastereoselectivity (1 : 1). Fortunately, replacing Bu_3P with a *P* chiral phosphine ligand **64** enabled the formation of the desired alcohol **65** with enhanced regioselectivity (2 : 1) and modest, but synthetically useful diastereoselectivity (3 : 1). Following functional group manipulation, the macrocycle was closed by intramolecular alkylation, similar to Myers' synthesis, using a cyclopentanone enolate generated from LiHMDS to give tricycle **66**. The next challenge the team was confronted with was the installation of the quaternary stereogenic center at C1. Notably, they discov ered that the presence of H_2O was crucial to achieve a successful α alkylation with NaH/MeI in toluene, which was attributed to producing finely dispersed NaOH *in situ*. Three further trans formations, namely deprotection, α hydroxylation *via* a potas sium enolate and ring opening of the resulting hemiketal followed by enolization led to the completion of the synthesis of ( ) terpestacin (**45**).

Later, in 2007, Trost and co workers published the fourth enantioselective total synthesis of ( ) terpestacin (**45**), exploiting the unusual reactivity of the diosphenol moiety (a cyclic 1,2 diketone with one ketone existing as an enol).[53] They planned to introduce chirality using the Pd catalyzed asymmetric allylic alkylation (AAA) methodology previously developed in their laboratories. The crucial macrocyclic ring closure was envisaged to proceed by means of a ring closing metathesis (RCM). Stereo convergent *O* alkylation of commercially available diosphenol **67** with racemic isoprene monoepoxide (**76**), employing AAA reaction conditions in the presence of Pd_2dba_3 and ligand (*R*,*R*) **74**, provided (after subsequent TIPS protection) allyl vinyl ether **68** in high yield (95%) and enantioselectivity (88 96% *ee*) (Scheme 9). A Claisen rearrangement was used to install the quaternary center, followed by a Saegusa Ito oxidation to form an α keto enone (not shown). The latter underwent a diastereo selective 1,4 Sakurai allylation to furnish cyclopentenone **69**, which in turn was converted into allylic bromide **70** over a simple three step sequence. This newly formed bromide **70** was then coupled to the dianion of sulfone **75** *via* alkylation, followed by a Pd catalyzed reductive desulfurization to cleanly afford RCM precursor **71**. Optimal results were observed with Grubbs' second generation catalyst, delivering the desired (*E*) configured mac rocycle **72**, albeit in moderate yield (35 44%). The final task remaining was to install the three carbon side chain. This problem was solved with a second AAA/Claisen rearrangement sequence. After PMB deprotection, allylic carbonate **77** was exposed to AAA conditions to facilitate *O* alkylation of the macrocycle's diosphenol moiety, immediately followed by a Claisen rearrangement under microwave irradiation.



Scheme 7 Myers' enantioselective synthesis of ( ) terpestacin and ( ) fusaproliferin employing a series of three diastereoselective enolate alkylations. TIPS triisopropylsilyl, KHMDS potassium hexamethyldisilazide, Red Al sodium bis(2 methoxyethoxy)aluminum hydride, Martin's sulfurane bis[α,α bis(trifluoromethyl)benzyloxy]diphenylsulfur, DMDO 3,3′ dimethyldioxirane, Ac_2O acetic anhydride, Ac acetyl.



Scheme 8 Jamison's asymmetric synthesis of ( ) terpestacin utilizing a Ni catalyzed intermolecular aldehyde/alkyne coupling. NMO *N* methyl morpholine *N* oxide, cod 1,5 cyclooctadiene, TMS trimethylsilyl, TBSOTf *tert* butyldimethylsilyl trifluoromethanesulfonate, TIPS triiso propylsilyl, TBAF tetrabutylammonium fluoride, KHMDS potassium hexamethyldisilazide.

Reprotection of the diosphenol gave PMB ether **73** as a virtually single diastereomer (>15 : 1) emerging from the overall reaction sequence. Only a short series of transformations remained necessary to complete the synthesis, including a reagent controlled Sharpless asymmetric dihydroxylation with AD mix α to oxidize the disubstituted side chain alkene chemoselectively in the presence of three trisubstituted alkenes. Following deprotection, Trost's group successfully synthesized ( ) terpestacin (**45**) in a total of 21 steps (longest linear sequence).

In the same year, Tius reported a 15 step synthesis of terpestacin (**45**) with an overall yield of 6.4%, albeit in a racemic fashion.[54] They envisaged the core α hydroxy enone structure originating from an allene ether Nazarov cyclization as a key step, forming one stereogenic center, which in turn would set all other stereogenic centers in the target. To this end, γ butyrolactone (**78**) was subjected to an one pot aldol/dehydration process with aldehyde **85**, then a subsequent isomerization protocol yielded the (*E*) configured lactone **79** in 66% yield (Scheme 10).[54b] After the addition of allenic lithium species **86** to lactone **79**, generating a hemiacetal (not shown), treatment with acid triggered the desired Nazarov cyclization and MOM deprotection to yield cyclopentenone **80**. This was followed by a two step sequence involving acetonide formation and diastereoselective hydrogenation to furnish enone **81**. Having installed the quaternary stereogenic center in cyclopentenone **82**, by alkylating the lithium enolate from ketone **81** with allylic bromide **87**, Tius' group turned their attention to closing the macrocyclic ring. In contrast to the previously discussed syntheses (but in analogy to the synthesis of Tatsuta), they planed to achieve this goal using a Horner Wadsworth Emmons reaction. Liberation of the free alcohol functionalities in phosphonate **82** by treatment with $Et_3N{\cdot}HF$, followed by DMP oxidation of both the primary and the secondary alcohols afforded the keto aldehyde macrocyclization precursor, which smoothly underwent macrocyclization in the presence of Hünig's base and LiCl, giving rise to tricycle **83**. Subsequently, a chemo and diastereoselective (dr 4 : 1) reduction of enone **83** was attained by exposure to a 1 : 1 mixture of *tert* BuLi/DIBAL H, and the resulting alcohol was protected as its TES silyl ether. Tius installed the last remaining methyl group in the side chain using a vinylogous enolate alkylation, leading to TES ether **84**. Despite the stereochemical outcome being the opposite required for terpestacin (**45**), it proved possible to invert the methyl group by formation of the corresponding TBS dienol ether and reprotonation with Cl_3CCOOH at low temperature. Finally, simultaneously cleavage of the TES ether and acetonide protecting groups with 1 N HCl gave rise to racemic terpestacin (**45**).

4.2 Dysidiolide

The bicarbocyclic sesterterpenoid ( ) dysidiolide (**88**) was isolated in 1996 and its relative configuration was established unambiguously by X ray crystallography (Fig. 6).[56] The hydroxybutenolide moiety undergoes rapid exchange at C25, resulting in a diastereomeric mixture. However, upon crystallization, this carbon exclusively assumes the configuration diagrammed below. A further remarkable feature of its geometry is that the large side chains each occupy axial and pseudoaxial positions on the same face of its decalin system.



Scheme 9 Trost's asymmetric synthesis of ( ) terpestacin exploiting an AAA/Claisen rearrangement sequence and an RCM macrocyclization. dba dibenzylideneacetone, TIPSOTf triisopropylsilyl trifluoromethanesulfonate, TMS trimethylsilyl, PMB *p* methoxybenzyl, TBAF tetrabutyl ammonium fluoride, LiHMDS lithium hexamethyldisilazide, dppp 1,3 bis(diphenylphosphino)propane, Boc *tert* butyloxycarbonyl.

In addition to its novel carbon skeleton at the time of its discovery, dysidiolide (**88**) was the first natural product reported to inhibit protein phosphatase cdc25a, an enzyme involved in dephosphorylation of cyclin dependent kinases, which have been proposed as potential anti cancer targets. Early results showed that dysidiolide (**88**) inhibits growth of A 549 human lung carcinoma and P388 leukemia cell lines.[57] Not surprisingly, a large number of synthetic chemists were drawn to dysidiolide (**88**) as a target, which culminated in several total and formal total syntheses. As a detailed discussion of all these approaches would exceed the range of this review, we will focus in the following on three successful syntheses by Corey,[58] Dani shefsky[59] and Forsyth.[60]

Just one year after its isolation, Corey's group presented the first route to ( ) dysidiolide (**88**).[58] They commenced their synthesis from the Wieland Miescher ketone analogue **89**, that was readily available in enantiomerically pure form (Scheme 11). A second quaternary stereogenic center was incorporated by Birch reduction and trapping of the resulting lithium enolate with allyl bromide, after which an enone was introduced by means of a sulfoxide elimination. This was followed by a Michael addition of TMS Li to generate β silyl ketone **90**, the purpose of which will be explained below. In a series of ten transformations, Corey converted ketone **90** into alcohol **91** by means of standard reactions as *e.g.* dihydroxylation, $NaIO_4$ cleavage, Wittig methylenation and a diastereoselective hydrogenation using Wilkinson's catalyst. Having obtained alcohol **91**, the stage was set for a biosynthetically inspired key step to construct the fully substituted bicyclic core of dysidiolide (**88**). Thus, treatment of tertiary alcohol **91** with gaseous BF_3 initiated the formation of a tertiary carbocation, triggering a methyl shift to form the desired quaternary stereogenic center, facilitated by the neigh boring TMS group due to hyperconjugation. The reaction was terminated by an elimination, extruding the TMS group and generating alkene **92** with the desired double bond regiochem istry. To extend the northern side chain, it was first necessary to cleave the primary TBS ether with PPTS and substitute the resulting alcohol for an iodide (not shown) prior to displacement with *iso* propenyl cuprate **95**. An additional two steps, namely deprotection of the primary alcohol and DMP oxidation yielded aldehyde **93**. One drawback late in the synthesis, however, was that addition of furan 3 yl lithium (**96**) to aldehyde **93** formed alcohol **94** as a mixture of diastereomers (1 : 1). To solve this problem, the (*S*) configured alcohol **94** was oxidized to the



(–)-dysidiolide (**88**)

Fig. 6 The molecular structure of the bicarbocyclic sesterterpenoid ( ) dysidiolide.



Scheme 10 Tius's racemic synthesis of terpestacin *via* an allene Nazarov cyclization. TIPS triisopropylsilyl, LiHMDS lithium hexamethyldisil azide, TsCl *p* toluenesulfonyl chloride, DBU 1,8 diazabicyclo[5.4.0]undec 7 ene, PPTS pyidinium *p* toluenesulfonate, LDA lithium diiso propylamide, DMP Dess Martin periodinane, DIPEA diisopropylethylamine, DIBAL H diisobutylaluminum hydride, TES triethylsilyl, HMPA hexamethylphosphoramide, TBSOTf *tert* butyldimethylsilyl trifluoromethanesulfonate, MOM methoxymethyl.

corresponding ketone, followed by a diastereoselective CBS reduction to give almost exclusively the (*R*) configured alcohol **94**. Ultimately, the photooxygenation of a furan utilizing Rose Bengal (Section 3.1 on manoalide) gave rise to ( ) dysidiolide (**88**) and thus established its absolute configuration.

The straightforward, but nevertheless linear synthesis by Corey started with the bicarbocyclic core of dysidiolide (**88**) already in place. In contrast, the convergent approach of Dani shefsky and co workers involved generating a more highly functionalized bicycle *via* an intermolecular Diels Alder reac tion.[59] Their syntheses were reported almost contemporaneously, although Danishefsky's route was not enantioselective. At the beginning of the synthesis, Danishefsky *et al.* subjected dioxolane **97** to dimethyl cuprate followed by trapping of the resulting anion with ethyl iodoacetate (**102**) (Scheme 12). A subsequent reduction and silylation sequence furnished compound **98**, which served as a masked dioxolenium dienophile. The other cycload dition partner, diene **100**, was assembled from lithium enolate **99** and alkyl iodide **103**, by successive enol triflate formation and Stille coupling to vinyl stannane **104**. The key Gassman Diels Alder reaction was carried out using TMSOTf as an acid catalyst (to activate dioxolane **98**, proceeding through the dioxolenium cation intermediate), in good yield with the desired regio and diastereoselectivity. As the bicycle **101** possessed the six stereo genic centers of dysidiolide (**88**) with the correct relative stereo chemistry, as well as the complete northern side chain, all that remained necessary were minor functional group interconver sions and elaboration of the southern appendage. This was accomplished first by a Wolff Kishner reduction that was accompanied by desilylation, and TPAP/NMO oxidation to yield aldehyde **93**, the same intermediate as in Corey's synthesis. Danishefsky completed the synthesis in a similar fashion to Corey, by nucleophilic attack of 3 furyllithium (**96**) and a pho tooxgenation in the presence of Rose Bengal (Scheme 11). The same diasteroselectivity problem from nucleophilic attack of the furyllithium species **96** onto aldehyde **93** was faced, but Dani shefsky's solution was to separate the isomeric products and invert the stereochemistry of the undesired alcohol **94** using Mitsunobu conditions.

Most of the other published syntheses of dysidiolide (**88**) are based on intermolecular Diels Alder reactions. A number of groups have employed the useful building block **106** that is readily available in enantiomerically pure form starting from racemic 2 methylcyclohexanone (**105**) using a method from d'Angelo (Scheme 13).[61] Among these groups are Boukouvalas,[62] Shirai[63] and Jung[64] who accomplished enantioselective total or formal total syntheses of ( ) dysidiolide (**88**) using similar Diels Alder approaches. Furthermore, Waldmann *et al.* prepared a model system containing the decalin core,[65] which was accompanied by the solid phase synthesis of analogues to carry out SAR studies.[66] Additionally, the group of Yamada reported both a racemic[67] and an asymmetric[68] total synthesis of ( ) dysidiolide (**88**), also utilizing an intramolecular Diels Alder reaction. Recently, Kaliappan and Gowrisankar reported a racemic formal total synthesis of dysidiolide (**88**) based on a dienyne metathesis to construct the dienophile portion.[69]

In 2000, however, Forsyth presented a conceptually different approach to racemic dysidiolide (**88**) featuring a diastereo selective sequential chirality transfer to install the stereogenic centers on its core.[60] His synthesis commenced with a diastereo selective *anti* alkylation of racemic keto ester **107**, which was followed by vinylogous ester formation and reductive 1,3 carbonyl transposition to yield enone **108** (Scheme 14). After protecting the primary alcohol as its TMS ether, the resulting enone was reacted with the higher order cyanocuprate generated from bromide **112**, *t* BuLi and CuCN to afford, after silyl ether cleavage, diol **109**. Having conducted a double oxidation with Jones' reagent and subsequent esterification of the resulting free



Scheme 11 Corey's asymmetric synthesis of ( ) dysidiolide. LDA lithium diisopropylamide, *m*CPBA *m* chloroperbenzoic acid, TMS trime thylsilyl, HMPA hexamethylphosphoramide, TBS *tert* butyldimethylsilyl, TBDPS *tert* butyldiphenylsilyl, PPTS pyridinium *p* toluenesulfo nate, TBAF tetrabutylammonium fluoride, DMP Dess Martin periodinane.



Scheme 12 Danishefsky's racemic synthesis of dysidiolide, TBDPS *tert* butyldiphenylsilyl, Tf_2O trifluoromethanesulfonic anhydride, TMSOTf trimethylsilyl trifluoromethanesulfonate, Mont. K10 montmorillonite K10, TPAP tetrapropylammonium perruthenate, NMO *N* methyl morpholine *N* oxide.

acid, Forsyth closed the six membered ring by means of an intramolecular aldol condensation in the presence of KO*t* Bu, yielding decalin **110**. The latter was treated with a cuprate prepared from bromide **113**, *t* BuLi, CuI, PBu_3 and BF_3 etherate to produce exclusively the 1,4 adduct **111** as a single diaste reomer with respect to the newly formed quaternary stereogenic center (the stereochemistry at the ring junction was not assigned). The authors commented that other cuprate reagents, such as those first described by Yamamoto, and other additives such as TMSCl offered no improved reactivity. Finally, a six step protocol led to aldehyde **93**, the common intermediate from the Corey and Danishefsky syntheses, that was converted to racemic dysidiolide (**88**) as previously described (Scheme 11). Other racemic formal syntheses by the groups of Piers[70] and Maier[71] were published in the same year, also opting to close the decalin system utilizing an intramolecular aldol condensation.

4.3 Miscellaneous bicarbocyclic sesterterpenoids

Apart from the two natural products discussed in the sections above, various other bicarbocyclic sesterterpenoids have been successfully synthesized during the past 20 years. The natural products (+) cladocoran A (**114**)[72] and (+) cladocoran B (**115**)[72] closely resemble dysidiolide (**88**), differing only by location of the alkene present in the decalin system. Their structures were originally misassigned after isolation, but total syntheses by the groups of Marcos[73] and Yamada[74] allowed for structural revision as depicted in Fig. 7. The synthesis of another structurally related natural product, (+) dysideapalaunic acid (**116**),[75] was disclosed in 1991 by Hagawira and Uda.[76] The authors chose to build around the decalin core, starting from a readily available enan tiomerically pure Wieland Mischer ketone analogue. In 1987, Piers and Wai[77] had reported a racemic synthesis of the



Scheme 13 d'Angelo's asymmetric synthesis of δ ketoester **106**.

antimicrobial sesterterpenoid (+) palauolide (**117**)[78] in 17 steps. Starting from 3,6 dimethylcyclohex 2 enone, they successfully installed the four contiguous stereogenic centers in the first four steps of their synthesis, while the remaining 13 steps adjusted the oxidation states and elaborated the side chain (not shown).

Two decades later, in 2002, Cheung and Snapper[79] published the total synthesis of the potent anti inflammotory marine metabolite (+) cacospongionolide B (**118**).[80] Within the short twelve step sequence, Snapper utilized an RCM to close the



Scheme 14 Forsyth's racemic synthesis of dysidiolide. TMS trime thylsilyl, *p*TsOH *p* toluenesulfonic acid, TBS *tert* butyl dimethylsilyl.

dihydrofuran moiety. Recently, the laboratories of Basabe[81] published an enantioselective route to the marine metabolite (+) luffalactone (**119**)[82] relying on a Yamaguchi lactonization and a photochemical oxidation of a furan as key steps.

Two other marine natural products, ( ) ircinianin (**120**)[83] and its cyclic isomer (+) wistarin (**121**)[84] have been the target of several synthetic studies (Scheme 15).[85] While Yoshii and Takeda[86] achieved an elegant biomimetic racemic synthesis of ircianinin (**120**), inspired by a biogenetic hypothesis put forward by Hofheinz,[83] Uenishi and co workes re examined this route eleven years later, completing an enantioselective synthesis in 1997.[87] They synthesized aldehyde **122** starting from the (*R*) Roche ester *ent* (**2**) (Section 2), which in turn underwent a Nozaki Hiyama Kishi (NHK) reaction with vinyl iodide **123**, followed by an intramolecular Diels Alder reaction to furnish the tricyclic adduct **124** in 60% yield. It is worth noting, the epimeric alcohol also formed in the NHK coupling did not cyclize spontaneously at room temperature, and could be iso lated from the reaction mixture (not shown). Further deoxy genation and demethylation led to ( ) ircinianin (**120**), which was converted to (+) wistarin (**121**) by iodoetherification and subsequent reductive deiodination. Interestingly, wistarin (**121**) was the first example of a sesterterpenoid that occurs naturally in both enantiomeric forms.[88]

Another family of bicarbocyclic sesterterpenoids, the leuco sceptroids,[89] represented by (+) leucosceptroid A (**125**)[89a] and (+) leucosceptroid D (**126**)[89b] has recently attracted the attention of Horne and co workers (Scheme 16).[90] Isolated in 2010 and 2011 from the small tree *Leucosceptrum canum*, these natural products possess anti feedant and anti fungal properties, provoking the authors to give them the moniker 'harbor defen sive sesterterpenoids.' Horne planned to use an intramolecular Diels Alder reaction to close the central six membered ring, and in their 2011 report, they described the synthesis of the Diels Alder precursor, triene **127**, in an enantioselective fashion. Exposing the latter to heat, in the presence of BHT, provided access to aldehyde **128**, efficaciously building up the tricyclic core of the leucosceptroids. Unfortunately, their attempts to intro duce the C6 methyl group, by alkene epoxidation and ring opening with an appropriate organometallic reagent, have not yet been successful.



Fig. 7 Molecular structures of successfully synthesized bicarbocyclic sesterterpenoids. Ac acetyl.

5 Tricarbocyclic sesterterpenoids

5.1 Gascardic acid

The group of Boeckman Jr. has demonstrated a longstanding interest in sesterterpenoid synthesis, producing a number of important contributions in this field. Among these contributions was their successful total synthesis of gascardic acid (**136**) in 1979,[91] the first truly structurally complex sesterterpenoid to have been made synthetically. Gascardic acid (**136**) was isolated in 1960,[92] and despite the careful investigation shortly following its isolation,[93] the relative configurations of the two side chain ster eocenters were not unambigously proven.[94] Thus, the synthesis by Boeckman *et al.* not only explored and pioneered new chemistry, but their work also clarified the structure of the natural product's unique molecular structure consisting of a [5 6 7] ring system and two adjacent quaternary stereogenic centers.



Scheme 15 (a) Molecular structures of ( ) ircinianin and (+) wistarin, (b) Uenishi's asymmetric synthesis: the key NHK/Diels Alder sequence to construct the tricyclic core structure. rt room temperature.

The Boeckman synthesis of gascardic acid (**136**) was initiated by a conjugate addition/annulation process: Michael addition to cyclopentenone **129**, employing mixed cuprate **137**, followed by trapping the resulting copper enolate with α trimethylsilylvinyl ketone **138**, succinctly provided (after workup and base mediated cyclization) the key hydrindenone **130** (Scheme 17). It was expected that such a cyclization would result in a *cis* relationship between the angular methyl group and the orientation of the side chain, based on earlier work in the same laboratories. The stereochemical outcome followed their prediction, unfortunately, however, the stereogenic center present in the side chain was formed as a mixture of epimers (1 : 1) and was carried forward without separation. The next task facing the authors was to install a second quaternary stereogenic center in a sterically congested position. Since strategies based on organo cuprate reagents were not successful, the group resorted to a [3,3] sigmatropic rearrangement to achieve the desired functionalization. Vinyl ether **131**, available in five steps from ketone **130**, was heated (160 °C) to affect a Claisen rearrangement, giving the desired aldehyde **132** as a single isomer in good yield (65%). After oxidation of the aldehyde to the corresponding acid, an iodolactonization was performed and the resulting intermediate lactone was directly converted to epoxide **133** by solvolysis with NaOMe and base mediated oxirane ring closure. Elaboration of this compound to *exo* methyene hydrindane **134** proved problematic, but could be accomplished in four steps. Lewis acid promoted rearrangement of the epoxide in **133** gave the thermodynamically more stable ketone. This was followed by saponification and an unusual olefination *via* adding lithium species **139** and subsequent reductive elimination. Finally, treatment with CH_2N_2 gave diester **134** in good overall yield. Closure of the final ring *via* a regioselective Dieckmann reaction was affected by treatment with LiTMP. The synthesis was then completed as follows: chemoselective reduction of the ketone, mesylation and elimination yielded the racemic methyl ester **135**. At that point, Boeckman *et al.* separated the mixture of epimers by means of liquid chromatography. Comparison of the spectral data revealed that their synthetic material was identical to an authentic sample of natural methyl gascardate. At last, saponification of methyl ester **135** delivered racemic gascardic acid (**136**). Later that year, Boeckman and Clardy verified the structure of gascardic acid (**136**) by X ray analysis of its dicyclohexylammonium salt.[95] However, the absolute configuration of this natural product has not been clarified to date.



Scheme 16 (a) Molecular structure of the sesterterpenoids (+) leucosceptroid A and D, (b) Horne's intramolecular Diels Alder approach. TBS *tert* butyldimethylsilyl, BHT 2,6 di *tert* butyl 4 hydroxytoluene.

5.2 Ophiobolins

The fungal metabolite (+) ophiobolin A (**140**)[96] was the first naturally occurring sesterterpenoid identified. Since its isolation in 1958, several congeners have been isolated showing the same carbon skeleton **A** (Fig. 8). In addition to their complex and structurally daunting [5 8 5] tricarbocyclic ring system, this class of natural products shows potent anti bacterial and anti fungal properties, as well as cytotoxicity in different cancer cell lines.[97] These characteristics have made the ophiobolins attractive targets for synthetic studies.[98] However, despite the considerable effort expended in such endeavours, only one synthesis of (+) ophiobolin C (**141**)[99] has been reported by the laboratories of Kishi in 1989,[100] and very recently, more than 50 years after its isolation, Nakada reported the total synthesis of (+) ophiobolin A (**140**) in 2011.[101]

Kishi *et al.* pointed out that one major challenge in the synthesis of the ophiobolin family rested on the difficulties associated with constructing the ring system, in particular the eight membered ring.[100,102] This problem was addressed by taking advantage of an intramolecular NHK reaction. At the beginning of their lengthy, but ultimately successful enantioselective route, Kishi *et al.* transformed 3 *endo* bromocamphor **142** over a series of six steps into alcohol **143**, setting two stereogenic centers of the natural product (Scheme 18).[103] After ozonolysis of the exocyclic double bond, protection of the primary alcohol and Saegusa Ito oxidation, then reduction of the enone under Luche conditions, allylic alcohol **144** was obtained (3 : 1 mixture in favor of the desired β isomer). The latter was coupled with acid chloride **152** under basic conditions, setting the stage for a domino Brook/Claisen rearrangement to install the pendant side chain of (+) ophiobolin C (**141**). The desired cascade took place upon heating the ester **145** at 230 °C in xylenes to yield (after hydrolysis of the intermediate silyl ester) acid **146** in high yield (72%) and good diastereoselectivity (6 : 1). With this important intermediate in hand, the functional groups were manipulated in a straightforward fashion over a nine step sequence, giving rise to aldehyde **147**. This product was treated with vinyl lithium reagent **153** (prepared asymmetrically starting from ( ) tartaric acid),[104] followed by re pivaloylation of the partially deacylated product to furnish the vinylogous hemiacetal **148**, which in turn underwent hydrolysis to the enone (not shown). Another three step sequence consisting of iododesilylation, selective deprotection of the THP ether and Swern oxidation finally provided aldehyde **149** as the key intermediate for the NHK reaction. In this event, subjecting aldehyde **149** to a large excess of $CrCl_2$ and a catalytic amount of $NiCl_2$ led to the desired key C C bond formation, successfully installing the [5 8 5] tricarbocyclic framework in alcohol **150**. The product was obtained as a single isomer with its relative stereochemistry assigned according to model studies, without being unambiguously proven.[104] To complete the remaining functional group



Scheme 17 Boeckman's racemic synthesis of gascardic acid showcasing the utility of [3,3] sigmatropic rearrangements to install quaternary stereogenic centers in congested positions. LiTMP 2,2′,6,6′ tetramethylpiperidinyl lithium, Ms methanesulfonyl, DBU 1,8 diazabicyclo[5.4.0]undec 7 ene, TMS trimethylsilyl.



Fig. 8 Molecular structures of (+) ophiobolin A, (+) ophiobolin C and the ophiobolin skeleton.

manipulations needed, Kishi *et al.* transposed the allylic alcohol *via* epoxidation of the exocyclic double bond, then thiocarbonate formation and Sn mediated radical reductive ring opening, that was accompanied by diastereoselective conjugate reduction of the enone, to yield alcohol **151**. An additional six steps finally provided (+) ophiobolin C (**141**) with analytical data in agree ment with that obtained from an authentic sample.

30 years after Kishi's synthesis of ophiobolin C (**141**), Nakada and co workers presented their successful route toward (+) ophiobolin A (**140**).[101] Within that time range, powerful synthetic tools were developed that provided new opportunities to address complex synthetic targets. Hence, Nakada *et al.* envisaged to close the B ring of ophiobolin A (**140**) by means of an RCM reaction. The authors stated that such a reaction to install a tri substituted double bond in an eight membered ring is highly challenging and not well precedented in the literature. Moreover, they planned to generate the spirocyclic tetrahydro furan moiety *via* a Lewis acid promoted cyclization. Their route was initiated by an enzymatic desymmetrization, giving rise to acid **154**, containing one quaternary stereogenic center, in 96% *ee* (Scheme 19). Following that, a 15 step sequence was required to prepare alkyl iodide **155**. Subsequent treatment with *t* BuLi generated the corresponding organo lithium species, which was trapped by enantiomerically pure lactone **163** (prepared *via* diastereoselective α allylation chemistry employing an Evans' auxiliary) to provide hemiketal **156**. After which, the above mentioned cyclization was explored, discovering that exposure of lactol **156** to BF_3 etherate resulted in the formation of spirocycle **157**, albeit in a modest yield of 45%.[105,106] Nakada *et al.* then shifted their focus toward closing the eight membered ring. To this end, the terminal alkene **157** was hydroborated and the resulting primary alcohol protected as its pivaloyl ester. Cleavage of the MOM ether and Dess Martin oxidation gave rise to aldehyde **158**, that was subjected together with cyclopentanone **164** to Reformatsky type reaction conditions, using Ph_3SnH and Et_3B. The boron enolate generated *in situ* reacted smoothly with aldehyde **158** to furnish the aldol product as a single isomer (90% yield, not shown), which was subsequently dehydrated with Burgess reagent to give enone **159** as a single diastereomer.

Next, the authors set the last two stereogenic centers in ophiobolin A (**140**) by taking advantage of substrate control: hydrogenation in the presence of RANEY® Ni followed by exposure to MeLi yielded diol **160** with excellent diastereo selectivity, cleaving the pivaloyl ester in the process. A rather long, 15 step sequence was needed to arrive at the RCM precursor, diene **161**, mainly due to protecting group



Scheme 18 Kishi's asymmetric synthesis of (+) ophiobolin C using an intramolecular NHK reaction. DHP 3,4 dihydro 2*H* pyran, PPTS pyr idinium *p* toluenesulfonate, Saegusa Ito TMS enol ether formation, then $Pd(OAc)_2$, THP 2 tetrahydropyranyl, KHMDS potassium hexame thyldisilazide, Piv pivaloyl, TMS trimethysilyl, TBAF tetrabutylammonium fluoride, *p*TsOH *p* toluenesulfonic acid, Swern Me_2SO, $(COCl)_2$, then Et_3N, TBDPS *tert* butyldiphenylsilyl, py pyridine, acac acetylacetone, AIBN 2,2′ azobis(2 methylpropionitrile), TBS *tert* butyldimethylsilyl, Bn benzyl.

manipulations, owing to the RCM reaction's sensitivity toward steric congestion. They were ultimately successful, however, as subjecting diene **161** to the Grubbs Hoveyda II catalyst in the presence of 1,4 benzoquinone at 110 °C closed the eight membered ring, yielding diol **162**. Having correctly set all ster eogenic centers and established the tetracyclic framework, Nakada *et al.* finished the synthesis employing a straightforward six step protocol to give, at long last, the first successful total synthesis of (+) ophiobolin A (**140**).

5.3 Ceroplastins

Shortly following the identification of the ophiobolins, was the discovery of other di and sesterterpenoids bearing a [5 8 5] tri carbocyclic core. As mentioned earlier, synthesis of such a carbon skeleton was considered challenging, especially the central eight membered ring, thus these natural products provided a platform to develop new synthetic methods for the generation of medium sized rings.[98,102] One class of such sesterterpenoids possessing a [5 8 5] system includes the ceroplastins, represented by (+) ceroplastol I (**165**),[107] (+) cer oplastol II (**166**)[108] and (+) albolic acid (**167**),[109] as shown in Fig. 9. The carbon skeleton of the ceroplastins bears a likeness to that of the ophiobolins, and the first synthesis of *rac* ceroplastol I (**165**) was reported by Boeckman *et al.* as a back to back publication in the same issue as Kishi's total synthesis of (+) ophiobolin C (**141**).[110]

Contrary to Kishi's strategy (forming the eight membered ring using a NHK reaction), Boeckman constructed the eight membered ring *via* the fragmentation of an appropriately func tionalized [3.3.1] nonanone system. To achieve this goal, they quickly built up a tricyclic system, starting from racemic bis carbonyl compound **168**, by conjugate addition to Michael acceptor **177**, followed by *p*TsOH mediated aldol condensation to yield tricyclic enone **169** as a 4.9 : 1 mixture of epimers (Scheme 20). Exploiting the bias of the tricyclic system, the group installed the quaternary stereogenic center in lactone **170** with complete stereocontrol during a five step sequence, involving three carbon chain extension and cyclization. A diaster eoselective Michael addition to enone **170** was accomplished using mixed cuprate **178**, and the resulting lactone was sol volyzed with LiOMe to furnish ester **171**. The [3.3.1] nonane scaffold was then built using a series of redox reactions. Although the authors did not specify the precise identity of the



Scheme 19 Nakada's enantioselective synthesis of (+) ophiobolin A employing an RCM to construct the eight membered ring. Ph phenyl, TMS trimethylsilyl, MOM methoxymethyl, TBDPS *tert* butyldiphenylsilyl, 9 BBN 9 borabicylo[3.3.1]nonane, Piv pivaloyl, DMP Dess Martin periodinane, Burgess reagent (methoxycarbonylsulfamoyl)triethylammonium hydroxide, inner salt, TBS *tert* butyldimethylsilyl, Bn benzyl.

intermediates in this sequence, it involved a Dieckmann cyclization that ultimately gave rise to tricyclic ketone **172**. An additional four step protocol, including a regio and diastereoselective reduction of the diketone with $LiAl(O\textit{t}\ Bu)_3H$, eventually leading to mesylate **173**, the substrate for the key Grob fragmentation reaction. As expected, treating ketone **173** with NaOMe in boiling MeOH resulted in the formation of diester **174**, bearing a suitably functionalized eight membered ring. After establishing the [5 8 5] tricarbocyclic framework *via* another Dieckmann condensation followed by Krapcho decarboxylation, the authors converted the resulting cyclopentanone under Saegusa Ito conditions into enone **175**. In order to install the side chain, Michael acceptor **175** was reacted with cuprate **179** to yield ketone **176** as an inseparable 1 : 1 mixture of epimers. The next task at hand was to deoxygenate, and Boeckman *et al.* were pleased that the transformation of ketone **176** to the corresponding tosylhydrazone not only cleaved the TBS ether as well, but also allowed for separation of the epimers (from the cuprate addition) by preparative TLC. Finally, reduction under quite forcing conditions using $ZnCl_2/NaCNBH_3$ in MeOH (90 °C) afforded racemic ceroplastol I (**165**).

In 1993, Paquette and co workers presented an enantioselective route to (+) ceroplastol I (**165**).[111] They began by utilizing the readily available asymmetric building block: acetal protected ketone **180**, and converted it into lactone **181** over ten steps (Scheme 21). The latter underwent a sequential Tebbe olefination/Claisen rearrangement, generating (*via* diene **182**) the eight membered ring with a *cis* junction that could be equilibrated with methanolic K_2CO_3 to yield the *trans* fused bicycle **183**. After 1,3 carbonyl transposition, requiring five steps, Paquette *et al.* obtained enone **184** and used cuprate **186** to introduce the last ring, employing a Michael addition/annulation protocol developed earlier by Piers.[112] Prior to finishing the synthesis with an endgame similar to that reported by Boeckman, Paquette transformed the resulting ketone in tricycle **185** into a trisubstituted alkene *via* formation of the corresponding enol triflate and subsequent methyl cuprate addition.

In comparison to (+) ceroplastol I (**165**), its double bond isomer (+) ceroplastol II (**166**) is lacking one stereocenter, as the exocyclic double bond present in the former is shifted one carbon over in the latter, situating it at the ring junction. Nevertheless, this sesterterpenoid **166**, as well as its oxidized form (+) albolic acid (**167**), resisted synthetic attempts until Kato *et al.* reported its first, and thus far only, total synthesis in 1988.[113,114] Over the course of this endeavor, the group planned to construct the crucial eight membered ring using a number of interesting



Fig. 9 Molecular structures of the ceroplastins.



Scheme 20 Boeckman's racemic synthesis of ceroplastol I constructing the eight membered ring *via* a Grob type fragmentation. DBN 1,5 di azabicyclo[4.3.0]non 5ene, *p*TsOH *p* toluenesulfonic acid, MOM methoxymethyl, EE ethoxyethyl, CAN ammonium cerium(IV) nitrate, OMs methanesulfonyl, Saegusa Ito lithium diisopropylamide, then $Pd(OAc)_2$, KHMDS potassium hexamethyldisilazide, TBS *tert* butyldi methylsilyl, $TsNHNH_2$ *p* toluenesulfonyl hydrazide, prep. TLC preparative thin layer chromatography.

transformations: a $CrCl_2$ mediated coupling, a [3,3] sigmatropic rearrangement and a pinacol coupling/cyclization. Their synthetic program initiated with racemic ester **187**, which underwent a $TiCl_2$ mediated reductive cyclization to yield diol **188** as the major product (Scheme 22). To render their synthesis asymmetric, the authors conducted an optical resolution of the corresponding acid. Further transformations delivered both enantiomers of aldehyde **189** over a total of eight steps each.[114c] It is noteworthy that this classical resolution cannot be considered wasteful, since both enantiomers were eventually used in the synthesis. The aldehyde (*S*) **189** was transformed over six steps into allylic chloride **190**, which in turn was subjected to a $CrCl_2$ promoted reductive coupling with aldehyde (*R*) **189** in the pres ence of *iso* PrOH, providing alcohol **191** in 88% yield. The coupling product was converted over a sequence of six steps to TMS protected lactol **192**, which served as a substrate for an unusual oxy Cope rearrangement. The expected chair like tran sition state of such a rearrangement would have resulted in the wrong stereochemical outcome at the quaternary stereogenic center, so Kato *et al.* biased the system to adapt a normally disfavored boat like transition state, by sequestering the hydroxy group in a six membered silyl lactol. Upon heating this lactol **192** to 190 °C, the rearranged dihydropyran **193** was obtained in good yield. Next, the authors employed a series of chemical transformations to access bisaldehyde **194**, the precursor for the key reductive cyclization. Once again employing $TiCl_2$, dicar bonyl compound **194** cleanly underwent pinacol coupling to give diol **195** as a single diastereomer (the relative stereochemistry at one stereocenter could not be assigned unambiguously). A subsequent Birch reduction of the corresponding diacetate with concomitant cleavage of the pivaloyl ester gave rise to alcohol **196**, possessing the tricarbocyclic core of (+) ceroplastol II (**166**).

Extension of the side chain required seven additional steps, giving ester **197**, that was used to complete the total synthesis of two sesterterpenoids in a divergent manner: saponification of the ester with NaOH provided the corresponding acid, (+) albolic



Scheme 21 Paquette's asymmetric synthesis of (+) ceroplastol I exploiting a Tebbe olefination/Claisen rearrangement sequence. Tebbe Cp_2TiCl_2, $AlMe_3$ premixed.

acid (**167**), whereas treatment with $LiAlH_4$ resulted in the synthesis of (+) ceroplastol II (**166**).

5.4 Miscellaneous tricarbocyclic sesterterpenoids

In addition to the ophiobolanes, ceroplastols and gascardic acid, a few other tricarbocyclic sesterterpenoids have captured the attention of synthetic chemists. Most of this attention has been directed at natural products possessing the cheilanthane skeleton **B** (Fig. 10). This topic however, has been reviewed in detail by Ungur and Kulciţki in 2009,[115] and their account covers the completed syntheses of ( ) hyrthiosal (**198**),[116,117] which features a rearranged carbon skeleton. Since then, Fekih *et al.*[118] reported the semisynthesis of the cheilanthane sesterterpenoid ( ) petro saspongianolide R (**199**).[119]

The synthesis of another tricarbocyclic sesterterpenoid, ( ) nitiol (**200**) (Fig. 11),[120] a potent enhancer of IL 2 gene expression in human T cell lines, was attempted, and almost achieved, by Dake and co workers.[121] In their enantioselective approach, they constructed the carbon framework utilizing a Norrish Type I fragmentation (not shown), and successfully installed the *cis* relationship between the A ring methyl and *iso* propyl groups. However, due to a problematic deoxygenation, their attempts to convert dihydroxynitiane **201** into ( ) nitiol (**200**) have so far been unfruitful.[121b]

6 Tetracarbocyclic sesterterpenoids

6.1 Cerorubenic acid-III

( ) Cerorubenic acid III (**202**) was first isolated in 1983 by Naya *et al.*, and plays a role in insect communication (Fig. 12).[122] From a series of detailed NMR experiments, the authors assigned its structure as consisting of a unique tetracyclo[8.4.1.0.0]pentade cane skeleton with a pendant side chain, seven contiguous stereogenic centers and an embedded vinylcyclopropane motif, its alkene moiety residing at a bridgehead site.

A campaign that spanned more than a decade in the Paquette group has spawned several published approaches to ( ) ceror ubenic acid III (**202**),[123] culminating in a report of its total synthesis in 1998 that confirmed both the original structural assignment and its absolute configuration.[124] Their successful approach started from cyclohexenone **203**, by Michael addition of diethyl malonate, then saponification and decarboxylation to assemble 1,5 keto acid **204** (Scheme 23). An acid catalyzed Claisen condensation, followed by an intramolecular oxidative coupling that proceeded through a dienolate intermediate, gave access to C_S symmetric diketone **205**. Subsequent mono methylenation gave unsymmetrical ketone *rac* **206**, that was resolved by 1,2 addition with chiral lithiated sulfoximine **139** and separation of the resulting diastereomers by column chroma tography. Independent pyrolysis of each diastereomer furnished both antipodes of ketone **206** in optically pure form. After ster eoselective addition of vinylmagnesium bromide to afford alcohol **207**, the stage was set for the key step of the synthesis: an anionic oxy Cope rearrangement, a signature reaction of the Paquette group. Indeed, treating alcohol **207** with KHMDS in refluxing THF triggered the formation of tricyclic anti Bredt alkene **208** in a remarkably efficient 88% yield. In preparation for annulation of the D ring, a four step sequence gave silyl ether **209**, which in turn was attacked by the lithium salt of phosphine oxide **215**. Following desilylation and phosphinate elimination, the resultant isomeric enol ethers **210** were transformed into allylic iodide **211**, requiring seven synthetic operations. A Kno chel chain extension was used to insert a methylene unit, by reacting iodide **211** with ICH_2ZnI in the presence of CuI and LiI, extending the allylic iodide chain by one carbon unit to afford homoallylic iodide **212**. Paquette's various published approaches to ( ) cerorubenic acid III (**202**) explored several attempts to



Scheme 22 Kato's enantioselective synthesis of (+) ceroplastol II and (+) albolic acid: ring closure by a pinacol coupling. Bn benzyl, TMS tri methylsilyl, Piv pivaloyl, Ac_2O acetic anhydride.



Fig. 10 Molecular structures of the cheilanthane skeleton and the two members ( ) hyrtiosal and ( ) petrosaspongianolide R.

incorporate the final six membered ring, including two different Robinson annulation strategies.[123c,d] Ultimately, only a radical 6 *exo* cyclization tactic proved successful. Upon subjecting homoallylic iodide **212** to free radical generating conditions (*n* Bu_3SnH, AIBN) the authors obtained the cyclized product, ester **213**, with the desired stereochemistry at both of the newly formed stereogenic centers (single diastereomer at the ring junction, 4.9 : 1 mixture of epimers at the side chain). The details concerning the stereoselectivity of this key step are discussed at length in the full paper.[124] Stepwise redox/chain extension *via* successive Horner Wadsworth Emmons reactions delivered ( ) cerorubenic acid III methyl ester (**214**), that was indistin guishable from an authentic sample.

6.2 Miscellaneous tetracarbocyclic sesterterpenoids

Among the tetracarbocyclic sesterterpenoids, there exists a large subclass that is host to the scalarane scaffold **C** (Scheme 24).[125] Owing to their range of anti microbial and cytotoxic activities, scalaranes have been targets of numerous synthetic studies, many of which are semi syntheses starting from either a structurally related sesterterpenoid, or ( ) sclareol (**219**) (a readily available diterpene building block). The synthesis of scalaranes has already been summarized, together with a description of isolation and biological activities, in a review from 2004.[126] Since then, it has remained an active area of research, evidenced by successful syntheses of the scalaranes (+) scalarolide (**218**),[9,127] ( ) sester statin 4 (**217**),[128,129] its epimer ( ) sesterstatin 5 (**220**)[128,129] and (+) 16 deacetoxy 12 *epi* scalarafuranacetate (**221**)[130,131] recently appearing in the literature. Notably, the latter three completed targets exhibit potent cytotoxic activity, likely stimulating further synthetic and biological studies on related natural products and structural analogs within this compound class.

One such report has been published by Kamel and Slattery in 2009.[132] Therein, they accomplished the semisynthesis of 20



Fig. 11 Molecular structures of ( ) nitiol and Dake's advanced inter mediate **201**. TBDPS *tert* butyldiphenylsilyl.



Fig. 12 The molecular structure of ( ) cerorubenic acid III.

natural and synthetic scalarane analogues starting from the naturally abundant metabolite heteronemin (**216**).[133] In addition, they conducted biological tests regarding cytotoxicity against different cancer cell lines as well as anti microbial activities.

In 1997, Piers *et al.*[134] reported a synthesis of ( ) variecolin's (**222**)[135] [5 8 5] core (Scheme 25). The Piers group had nearly completed its total synthesis in 2002, as described in S. D. Walk er's Ph.D. thesis.[136] Unfortunately, they were unable to produce enough material to investigate the conversion of either racemic 5 deoxyvariecolin (not shown) into variecolin (**222**) or 5 deoxy variecolol (**223**) and 5 deoxyvariecolactone (**224**) into the corre sponding natural products.[137] At around the same time, in 2001, Molander's group published an enantioselective approach to the same target.[138] They planned to take advantage of a sequenced SmI_2 mediated coupling, which they expected to be a viable means to produce cyclooctanoid hemiketal **225**. Although their model studies demonstrated the general feasibility of the coupling step, only the asymmetric synthesis of the required building blocks 1,3 keto ester **226** and 4 chloro ketone **227** were reported, with no description of their use in the key coupling step so far.

Uemura *et al.*[139] developed an enantioselective route to the tetracarbocyclic core of mangicol A (**228**)[140] in 2004 (Fig. 13). They invoked a stereoselective transannular Diels Alder reac tion to access spirocycle **230**, possessing the majority of the requisite carbon skeleton and functionality. In addition to Uemura *et al.*, the Paquette group conducted initial studies aimed at establishing routes toward (+) mangicol A (**228**).[141] More recently, Sarpong *et al.* described a preliminary investiga tion into the synthesis of related structure (+) neomangicol C (**229**),[140] preparing tetracyclic ketone **231** as a racemate *via* intramolecular addition of an indene to an aldehyde.[142]

The sesterterpenoid YW3699 (**232**),[143] with its daunting [5 8 6 5] tetracarbocyclic core, is a potent inhibitor of GPI anchor biosynthesis, whose absolute configuration and relative config uration at the heptanoate side chain is unknown to date (Fig. 14). It drew the interest of Tori *et al.*, who prepared an advanced intermediate *en route* to the natural product, tricarbocycle **233**, using RCM to effectively close the central eight membered ring.[144] Noteworthy, the epimeric epoxide did not undergo ring closure. Their model system, however, has not yet addressed the installation of the crucial *trans* hydrindane moiety found in YW3699 and related molecules. With a *cis* relationship between its angular methyl and *iso* propyl substituents, this represents a significant synthetic challenge.

7 Pentacarbocyclic sesterterpenoids: Retigeranic acid

Among the known members of this rare sesterterpenoid class, ( ) retigeranic acid A (**234**)[145] remains the only one that has



Scheme 23 Paquette's asymmetric synthesis of ( ) cerorubenic acid III methyl ester featuring an anionic oxy Cope rearrangement and a free radical cyclization. PPA polyphosphoric acid, LDA lithium diisopropylamide, FCC flash column chromatography, KHMDS potassium hexame thyldisilazide, TBAF tetrabutylammonium fluoride, AIBN 2,2′ azobis(2 methylpropionitrile).

succumbed to chemical synthesis (Fig. 15). First isolated in 1965 from the Himalayan lichen *Lobaria retigera*,[145a] the structure of acid **234** was not fully assigned until seven years later by Shibata *et al.*, who were able to obtain an X ray crystal structure of its *p* bromoanilide derivative.[145c]

However, during the Corey group's pursuit of a retigeranic acid (**234**) total synthesis in the early 1980s (see below),[146] they discovered that an authentic sample of retigeranic acid, which they obtained from Shibata, was in fact a mixture of two dia stereomers. This was learned by the esterification of natural retigeranic acid with CH_2N_2, which enabled separation of the corresponding ester derivatives using HPLC. Furthermore, it was found that ( ) retigeranic acid A (**234**)[147] was actually the minor component of the mixture. The structure of the major component ( ) retigeranic acid B (**235**) was elucidated several years later using X ray crystallography and finally published in 1991, again by Shibata. It turned out that acid **235** differs from its counterpart **234** only by the *iso* propyl substituents' relative stereochemistry (Fig. 15).[145d] As a consequence of this molecule's complicated history, all four successful total syntheses targeted the originally reported structure of ( ) retigeranic acid (**234**), since the synthetic work was completed prior to Shibata disclosing the identity of ( ) retigeranic acid B (**235**).

From a synthetic chemist's point of view, retigeranic acid (**234**) can be thought to possess an intimidating molecular structure, being comprised of several noteworthy features: eight stereogenic centers, two of which are quaternary, and a unique penta carbocyclic skeleton. This framework includes a *trans* hydrin dane and a triquinane moiety that together comprise four five membered and one six membered ring. Remarkably, the molecule has only a single oxygenated site, namely a lone carboxylic acid functionality. Often labelled as a classic target in total synthesis,[148,149] retigeranic acid (**234**) has provided numerous challenges for the groups of Corey,[146] Paquette,[150] Hudlicky[151] and Wender,[152] all of whom were ultimately successful undertaking its synthesis.

The Corey group was the first to complete the total synthesis of retigeranic acid (**234**) in 1985, ensuring its subsequent popularity as a synthetic target.[146] One of the most obvious stumbling blocks they faced, the diastereoselective installation of the crucial quaternary center embedded within the triquinane system, was addressed elegantly with an intramolecular ketene/alkene [2 + 2] cycloaddition. It was anticipated that subsequent ring expan sion/ring contraction processes could be exploited to access to the required triquinane moiety. They elected to begin their synthesis from racemic hydrindenone **236**, which was readily available *via* Robinson annulation.[153] The authors chose to employ a substrate directed hydrogenation to set the *trans* ring junction in alcohol **237**, since formation of the strained *trans* hydrindane ring system is usually thermodynamically unfa vored.[154] A short sequence of functional group manipulations were carried out: a diastereoselective reduction of ketone **236** with $LiAlH_4$, followed by alcohol inversion using Mitsunobu conditions. Directed hydrogenation in the presence of cationic Rh catalyst **247** under high pressure (950 psi) furnished the desired *trans* hydrindane **237** (Scheme 26). Subsequently, the alcohol was re oxidized to the corresponding ketone using Jones' reagent. A two step protocol commencing with vinyl Grignard addition, followed by elimination of water yielded diene **238**, which in turn served as a substrate for the Diels Alder reaction with dienophile **248**. The desired [4 + 2] cycloadduct **239** was produced in 61% yield as the major isomer, and six additional steps were needed to prepare carboxylic acid **240**, the precursor for the key [2 + 2] cycloaddition. Treatment with oxalyl chloride



Scheme 24 (a) Molecular structures of the scalarane skeleton **C** and the natural product heteronemin, (b) recently reported semisyntheses of biologically active scalaranes starting from ( ) sclareol.



Scheme 25 (a) Molecular structure of ( ) variecolin, (b) deoxygenated natural products synthesized by Piers, (c) Molander's retrosynthetic analysis and building blocks **220** and **221** prepared in an enantioselective fashion. PG protecting group.



Fig. 13 (a) Molecular structures of (+) mangicol A and (+) neo mangicol C, (b) core structure **230** asymmetrically prepared by Uemura *via* a Diels Alder reaction, (c) Sarpong's racemic tetracyclic intermediate **231**.



Fig. 14 Molecular structures of GPI anchor inhibitor YW3699 and Tori's tricarbocycle **233** prepared by RCM.



Fig. 15 Molecular structures of ( ) retigeranic acids A and B.

and Et_3N generated the corresponding ketene **241** *in situ*, smoothly giving rise to cyclobutanone **242** in 80% yield, thereby accomplishing diastereoselective incorporation of the all carbon quaternary center. The ring expansion of cyclobutanone **242** to the corresponding cyclopentanone was initiated by the addition of lithiated dithiane **249**, giving rise to carbonyl adduct **243** in 73% yield. A subsequent CuOTf mediated thio pinacol rearrangement in the presence of Et_3N was followed by a two step desulfurization sequence: oxidation with $NaIO_4$ and then reductive C S bond cleavage with Al/Hg. The resulting cyclopentanone **244**, obtained in 65% overall yield, was later transformed into alkene **245** over a five step sequence that included olefin hydrogenation, methyl group epimerization and deoxygenation *via* modified Wolff Kishner reduction. The final remaining hurdle was to introduce the triquinane motif *via* ring contraction. This was made possible in four steps, starting with OsO_4 promoted dihydroxylation, followed by glycol cleavage with $Pb(OAc)_4$ yielding dialdehyde **246** that was surrendered to Al_2O_3, which affected aldol ring closure. At long last, a Pinnick oxidation concluded the synthesis, providing access to racemic retigeranic acid (**234**) in 32 steps (longest linear sequence).

In contrast to Corey's linear synthesis, Paquette *et al.* adopted a more convergent strategy in their enantioselective route to ( ) retigeranic acid (**234**), reported in 1987.[150] They intended to attach the A ring *via* 1,4 addition to a triquinane fragment then close the B ring late in the synthesis using an intramolecular aldol condensation. The required triquinane building block **259** was synthesized starting from (+) pulegone (**250**).[155] The latter was brominated, then treated with NaOMe to trigger a Favorskii rearrangement with concomitant elimination of bromide. Subsequent ozonolysis yielded cyclopentanone **251**,[156] that was alkylated with tosylate **253** under basic conditions (Scheme 27). A ketone functionality was then unmasked by ozonolysis, enabling ring closure by aldol condensation. Subsequent heating of the product in the presence of LiI affected decarboxylation of the ester, yielding bicyclic enone **252** as a separable 2 : 1 mixture of diastereomers. The remaining two stereogenic centers in triquinane **259** were set in two steps: a diastereoselective Michael addition of the cuprate derived from Grignard reagent **254**, followed by HCl mediated acetal hydrolysis that resulted in spontaneous aldol cyclization and furnished triquinane **257** as a mixture of epimers. Next, thiocarbonate formation and subsequent Chugaev type elimination yielded alkene **258**. Finally, Wolff Kishner reduction and a chromium mediated allylic oxidation of the corresponding hydrocarbon gave access to the desired triquinane building block **259**. It is worth noting that formation of enone **259** was accompanied by significant amounts (*ca.* 30%) of the undesired 1,3 transposed enone. This certainly represented a drawback, since separation from the desired product was only possible upon reduction to the alcohol stage, thus an extra re oxidation step was added to the sequence employed to obtain pure tricyclic ketone **259**.

Paquette *et al.* once again turned to the chiral pool for the synthesis of the second fragment, choosing to start from ( ) limonene (**260**).[157] It was possible to access allylic alcohol **261** in six steps, which in turn was converted into ketone **262** *via* Wittig Still rearrangement (utilizing stannane **256**) followed by ozonolysis and TBS protection. Formation of cylcopentenone **263** from ketone **262** required adjustment of both functionality and relative stereochemistry. This net conversion was achieved using a four step protocol that involved 1,3 ketone transposition/enone formation, followed by the 1,4 addition of vinyl cuprate (dr 77 : 23). Completion of the second fragment was accomplished by Wolff Kishner reduction with simultaneous desilylation, and conversion of the primary alcohol to bromide **264** with $ZnBr_2$/DEAD/PPh_3. The authors commented that the latter transformation was exceptionally difficult due to the alcohol being neopentylic and only Mitsunobu type conditions proved effective. Having established viable routes to both fragments, Paquette and co workers explored the key coupling step, discovering that the Grignard reagent derived from alkyl bromide **264** underwent exclusive 1,4 addition to sterically hindered enone **259**. Unfortunately, however, after ozonolysis of the addition product, aldehyde **265** was obtained as the minor diastereoisomer (dr 1 : 3), indicating that the 1,4 addition was unselective. Closing the B ring *via* aldol condensation required quite harsh conditions, namely piperidine and HOAc in hot toluene for 48 h. These conditions led to partial epimerization of the aldehyde at the α position, producing the desired *trans* configured product as the minor diastereomer (dr 1 : 4, separated at the end of the synthesis by HPLC) and in modest combined yield. The resulting enone system was hydrogenated in the presence of PtO_2 under elevated pressure (80 psi), giving rise to an epimeric mixture of ketones **266**. Paquette *et al.* were able to finish the synthesis in four additional steps. First, ketone **266** was homologated *via* high pressure (100 000 psi) cyanohydrin formation in the presence of KCN and 18 crown 6, then dehydrated with $POCl_3$ and DBU in boiling pyridine to give the corresponding α,β unsaturated nitrile. Finally, DIBAL H reduction and Pinnick oxidation provided ( ) retigeranic acid (**234**), constituting its first asymmetric preparation.

Despite the convergent nature of Paquette's synthesis, it nevertheless required a large number of steps (26 steps, longest linear sequence), and suffered from modest yields, especially due to the low stereoselectivities obtained in late stage transformations. One year after Paquette's work was published, Hudlicky and co workers reported a shorter asymmetric synthesis of ( ) retigeranic acid (**234**) with a longest linear sequence of only 18 steps.[151] Their strategy hinged on generating the pentacyclic framework by forming the C ring *via* a [2 + 3] annulation, involving the thermolysis of a vinyl cyclopropane (*vide infra*). Hudlicky *et al.* selected (+) menthene (**267**) as a starting material, carrying out its ozonolysis in the presence of *p*TsOH/MeOH to protect the *in situ* formed aldehyde as its dimethyl acetal. Regeneration of the aldehyde under mild acidic conditions was followed by direct conversion to enamine **268** (Scheme 28). The latter was ozonolyzed, excising one carbon unit to reveal an aldehyde. A subsequent HWE reaction with phosphonate **275** was used to install a diene. Wittig methylenation of the remaining methyl ketone then gave triene **269** setting the stage for an intramolecular Diels Alder reaction to produce the indane skeleton in ester **270**. This transformation proceeded diastereoselectively, but produced an inconsequential mixture of double bond isomers in modest yield. Enol ether hydrolysis and Krapcho decarboxylation finally yielded enantiomerically pure hydrindane **271**,[158] which incidentally, also served as an intermediate in Corey's retigeranic acid synthesis, albeit as a racemate. In preparation for the key step, hydrindane **271** was condensed with ethyl trimethylsilylacetate (**276**), and after sequential bromination/monodehydro bromination, ester **272** was obtained. With this compound in hand, Hudlicky *et al.* were poised to explore their annulation strategy. Adding the LDA derived dienolate of ester **272** to enone **252** (*cf.* Scheme 27), at 100 °C resulted in 1,4 addition and subsequent nucleophilic substitution, forming vinylcyclopropane **273** as an 1 : 1 mixture of stereoisomers. Subsequently, flash vacuum pyrolysis of each isomeric vinylcyclopropane **273** gave rise to ketone **274** with good diastereoselectivitiy (4 : 1 to 2 : 1, depending on the isomer used).[151a] From this point, erasure of the ketone was accomplished in three steps by ketone reduction and Barton McCombie deoxygenation. Finally, saponification of the ethyl ester that followed concluded their elegant total synthesis of ( ) retigeranic acid (**234**).

The most recent synthesis of retigeranic acid (**234**) reported thus far came from the Wender group in 1990.[152] Intending to close the B ring at a late stage *via* an intramolecular Diels Alder reaction, their plan was contingent on construction of the triquinane portion by employing a photochemical arene alkene cycloaddition, a methodology previously developed in their



Scheme 26 Corey's racemic synthesis of retigeranic acid employing a ring expansion/contraction strategy to install the quaternary center of the tri quinane subunit. DEAD diethyl azodicarboxylate, Pinnick $NaClO_2$, NaH_2PO_4, *t* BuOH.

laboratories. Starting from half ester **277** (readily available in 99% *ee* by enzymatic resolution of 3 methyl glutaric dimethyl ester), six steps were required to furnish arene **278** (Scheme 29). The pivotal photochemical cycloaddition proceeded efficiently, but unfortunately furnished the desired tetracycle **279** as the minor isomer (1 : 2 selectivity). It is noteworthy however, that this transformation rapidly builds complexity and was suitable for preparing multi gram quantities of tetracycle **279**. Cyclopropane ring opening and installation of the correct functionality was accomplished by exposure to an acyl radical, generated photochemically from formamide, resulting in addi tion to the alkene and fragmentation of the intermediate cyclo propylcarbinyl radical. The resulting amide product **280** was then methylated, yielding triquinane **281**, followed by allylic oxidation with SeO_2 to deliver aldehyde **282**. Condensation of the latter with the dianion of acid **287** (available in four steps from (*R*) ( ) carvone) and subsequent decarboxylative dehy dration afforded triene **283**. Heating this Diels Alder precursor (toluene, 250 °C) yielded cycloadduct **284** as the major isomer along with two isomers (one diastereomer, one double bond regioisomer). Unfortunately, however, further isomerization of the double bond into conjugation with the amide was problem atic, and the authors instead opted for an indirect method by epoxidation, base mediated ring opening and dehydration to yield diene **285**. Poor selectivity was observed for the following high pressure hydrogenation step, furnishing the desired stereoisomer of pentacyclic amide **286** in only 25% yield. It was possible however, to recycle the other isomeric products obtained from this reaction. With simply oxidation state adjustment required for completion of the synthesis, amide **286** was reduced with $LiAlH_4$, followed by stepwise oxidation using PDC and Pinnick conditions, yielding ( ) retigeranic acid (**234**) after 20 steps (longest linear sequence). Similar to Paquette, Wender's approach was plagued by late stage selectivity problems that were detrimental to the overall efficiency of the synthesis, leaving room for improvement from future generations of synthetic chemists. Since the 1990s however, no additional data toward the synthesis of either ( ) retigeranic acid (**234**) or its diastereomer, ( ) retigeranic acid B (**235**) (Fig. 15), have surfaced in the liter ature. Furthermore, to the best of our knowledge, no synthetic groups have reported progress toward any other members of this rare and beautiful class of sesterterpenoids.

8 Conclusions

Herein, we have presented a few dozen total syntheses that have yielded sesterterpenoids of varying complexity, ranging from simple linear molecules to highly complex polycyclic systems. These syntheses have featured much of the repertoire of modern chemistry, including transition metal catalyzed C C bond formations and macrocyclizations, cycloadditions, and rear rangements. The rather lengthy sequences needed in many cases,



Scheme 27 Paquette's asymmetric synthesis of ( ) retigeranic acid featuring a Grignard reagent 1,4 addition and an aldol condensation to close the B ring at last. py pyridine, HOAc acetic acid, Ac_2O acetic anhydride, TBS *tert* butyldimethylsilyl, DEAD diethyl azodicarboxylate, TMS trimetylsilyl, DBU 1,8 diazabicyclo[5.4.0]undec 7 ene, 18 C 6 1,4,7,10,13,16 hexaoxacyclooctadecane, DIBAL H diisobutylaluminum hydride, Pinnick $NaClO_2$, NaH_2PO_4, 2 methyl 2 butene, *t* BuOH.



Scheme 28 Hudlicky's enantioselective synthesis of ( ) retigeranic acid utilizing a vinylcyclopropane rearrangement. *p*TsOH *para* toluenesulfonic acid, LDA lithium diisopropylamide, DBU 1,8 diazabicyclo[5.4.0]undec 7 ene, AIBN 2,2′ azobis(2 methylpropionitrile), TMS trimethylsilyl.



Scheme 29 Wender's asymmetric synthesis of ( ) retigeranic acid generating the triquinane subunit *via* a photochemical arene alkene cycloaddition. py 2 pyridyl, LDA lithium diisopropylamide, *m*CPBA *m* chloroperbenzoic acid, PDC pyridinium dichromate, Pinnick $NaClO_2$, NaH_2PO_4, *t* BuOH.

e.g. in the synthesis of ophiobolin A (**140**) or retigeranic acid A (**234**), reflect the structural complexity of sesterterpenoids but also suggest that there is some room for improvement. It may be worth revisiting some of the classic targets armed with a new set of reagents and growing confidence that reactions can be carried out with high chemoselectivity, thus avoiding protecting group operations. As new members of the sesterterpenoid family are discovered, and largely forgotten ones are unearthed, modern synthetic methods will continue to be developed and refined using this fascinating class of natural products.

9 Acknowledgements

The authors are grateful to the *Fonds der Chemischen Industrie e. V.* (Ph.D. Scholarship to D.T.H) and the *Alexander von Hum boldt Stiftung* (Post doctoral fellowship to R. W.) for financial support. We thank Sebastian Strych for proofreading the manuscript.

10 References and notes

1 For early examples of Komppa's work on camphor, see.: (*a*) G. Komppa, *Ber. Dtsch. Chem. Ges.*, 1903, **36**, 4332 4335; (*b*) G. Komppa, *Chem. Ber.*, 1909, **41**, 4470 4474.
2 For reviews on the isolation of sesterterpenoids, see *e.g.*: (*a*) Y. Liu, L. Wang, J. H. Jung and S. Zhang, *Nat. Prod. Rep.*, 2007, **24**, 1401 1429; (*b*) J. R. Hanson, *Nat. Prod. Rep.*, 1996, **13**, 529 535; (*c*) J. R. Hanson, *Nat. Prod. Rep.*, 1992, **9**, 481 489; (*d*) J. R. Hanson, *Nat. Prod. Rep.*, 1986, **3**, 123 132; (*e*) J. R. Hanson, in *Terpenoids and Steroids*, ed. K. H. Orton, The Chemical Society, London, 1974, vol. 4, p. 171; (*f*) G. A. Cordell, *Phytochemistry*, 1974, **13**, 2343 2364.
3 For reviews on marine natural products, see *e.g.*: (*a*) J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro and M. R. Prinsep, *Nat. Prod. Rep.*, 2012, **29**, 144 222; (*b*) J. W. Blunt, B. R. Copp, M. H. G. Munro, P. T. Northcope and M. R. Prinsep, *Nat. Prod. Rep.*, 2011, **28**, 196 268; (*c*) J. W. Blunt, B. R. Copp, M. H. G. Munro, P. T. Northcope and M. R. Prinsep, *Nat. Prod. Rep.*, 2010, **27**, 165 237; (*d*) J. W. Blunt, B. R. Copp, W. P. Hu, M. H. G. Munro, P. T. Northcote and M. R. Prinsep, *Nat. Prod. Rep.*, 2009, **26**, 170 244; (*e*) J. W. Blunt, B. R. Copp, W. P. Hu, M. H. G. Munro, P. T. Northcote and M. R. Prinsep, *Nat. Prod. Rep.*, 2008, **25**, 35 94; (*f*) J. W. Blunt, B. R. Copp, W. P. Hu, M. H. G. Munro and P. T. Northcope, *Nat. Prod. Rep.*, 2007, **24**, 31 86; (*g*) D. J. Faulkner, *Nat. Prod. Rep.*, 2002, **19**, 1 49 and further reviews in this series.
4 For a review on terpenes from marine derived fungi, see: R. Ebel, *Mar. Drugs*, 2010, **8**, 2340 2368.
5 For a review on bioactive sester and triterpenes from marine sponges, see: S. S. Ebada, W. Lin and P. Proksch, *Mar. Drugs*, 2010, **8**, 313 346.
6 For the isolation of okinonellin B, see: Y. Kato, N. Fusetani, S. Matsugaga and K. Hashimoto, *Experientia*, 1986, **42**, 1299 1300.
7 For the synthesis of okinenollin B, see: W. D. Schmitz, N. B. Messerschmidt and D. Romo, *J. Org. Chem.*, 1998, **63**, 2058 2059.
8 Y. Noda, H. Hashimoto and T. Norizuki, *Heterocycles*, 2001, **55**, 1839 1841.
9 For the isolation of idiadione and scalarolide, see: R. P. Walker, J. E. Thompson and D. J. Faulkner, *J. Org. Chem.*, 1980, **45**, 4976 4979.
10 (*a*) D. J. Faulkner, *Tetrahedron Lett.*, 1973, **14**, 3821 3822; (*b*) C. J. Barrow, J. W. Blunt, M. H. G. Munro and N. B. Perry, *J. Nat. Prod.*, 1988, **51**, 275 281.
11 K. Takabe, H. Hashimoto, H. Sugimoto, M. Nomoto and H. Yoda, *Tetrahedron: Asymmetry*, 2004, **15**, 909 912.
12 For isolation and biological properties of palinurin, see: (*a*) G. Alfano, G. Cimino and S. De Stefano, *Experientia*, 1979, **35**, 1136 1137; (*b*) K. A. El Sayed, A. M. S. Mayer, M. Kelly and T. Hamann, *J. Org. Chem.*, 1999, **64**, 9258 9260.

13 For the synthesis of palinurin, see: M. Pérez, D. I. Pérez, A. Martínez, A. Castro, G. Gómez and Y. Fall, *Chem. Commun.*, 2009, 3252 3254.
14 (*a*) R. Tschesche, F. X. Brock and I. Duphorn, *Tetrahedron Lett.*, 1968, **9**, 2905 2909; (*b*) R. Tschesche, F. X. Brock and I. Duphorn, *Justus Liebigs Ann. Chem.*, 1968, **720**, 58 70; (*c*) W. A. Slusarchyk and F. L. Weisenborn, *Tetrahedron Lett.*, 1969, **10**, 659 662.
15 For a mini review on the antibiotic function of moenomycin A, see: J. van Heijenoort, *Glycobiology*, 2001, **11**, 25R 36R and references therein.
16 For the first total synthesis of moenomycin A, see: J. G. Taylor, Y. X. Li, M. Oberthur, W. Zhu and D. E. Kahne, *J. Am. Chem. Soc.*, 2006, **128**, 15084 15085.
17 For a review on syntheses around the transglycosylation step in peptidoglycan biosynthesis including a detailed discussion on the syntheses of moenocinol and diumycinol, see: P. Welzel, *Chem. Rev.*, 2005, **105**, 4610 4660.
18 R. Tschesche and J. Reden, *Justus Liebigs Ann. Chem.*, 1974, **1974**, 853 863.
19 P. A. Grieco, Y. Masaki and D. Boxler, *J. Am. Chem. Soc.*, 1975, **97**, 1597 1599.
20 (*a*) P. J. Kocienski, *J. Org. Chem.*, 1980, **45**, 2037 2039; (*b*) P. J. Kocienski and M. Todd, *J. Chem. Soc., Perkin Trans. 1*, 1983, 1777 1781.
21 R. M. Coates and M. W. Johnson, *J. Org. Chem.*, 1980, **45**, 2685 2697.
22 (*a*) D. Bottger and P. Welzel, *Tetrahedron Lett.*, 1983, **24**, 5201 5204; (*b*) U. Schuricht, L. Hennig, M. Findeisen, P. Welzel and D. Arigoni, *Tetrahedron Lett.*, 2001, **42**, 3835 3837.
23 M. C. Stumpp and R. R. Schmidt, *Tetrahedron*, 1986, **42**, 5941 5948.
24 H. J. Huang and W. B. Yang, *Tetrahedron Lett.*, 2007, **48**, 1429 1433.
25 G. Hilt and J. Treutwein, *Chem. Commun.*, 2009, 1395.
26 E. D. de Silva and P. J. Scheuer, *Tetrahedron Lett.*, 1980, **21**, 1611.
27 For an overview on the biochemistry of manoalide with related natural and unnatural structures, see: A. Soriente, M. De Rosa, A. Scettri, G. Sodano, M. Terencio, M. Payá and M. J. Alcaraz, *Curr. Med. Chem.*, 1999, **6**, 415 431.
28 S. Katsumura, S. Fujiwara and S. Isoe, *Tetrahedron Lett.*, 1985, **26**, 5827 5830.
29 M. E. Garst, E. A. Tallman, J. N. Bonfiglo, D. Harcourt, E. B. Ljungwe and A. Tran, *Tetrahedron Lett.*, 1986, **27**, 4533 4536.
30 S. Katsamura, S. Fujiwara and S. Isoe, *Tetrahedron Lett.*, 1988, **29**, 1173 1176.
31 (*a*) P. Bury, G. Hareau, P. J. Kocienski and D. Dhanak, *Tetrahedron*, 1994, **50**, 8793 8808; (*b*) A. Pommier and P. J. Kocienski, *Chem. Commun.*, 1997, 1139 1140.
32 J. Coombs, E. Lattman and H. M. R. Hoffmann, *Synthesis*, 1998, 1367 1371.
33 A. Soriente, M. De Rosa, A. Acipella, A. Scettri and G. Sodano, *Tetrahedron: Asymmetry*, 1999, **10**, 4481 4484.
34 A. Pommier, V. Stepanenko, K. Jarowicki and P. J. Kocienski, *J. Org. Chem.*, 2003, **68**, 4008 4013.
35 For the isolation of luffariolide E, see: M. Tsuda, H. Shigemori, M. Ishibashi, T. Sasaki and J. Kobayashi, *J. Org. Chem.*, 1993, **57**, 3503 3507.
36 For the synthesis and structural reassignment of luffariolide E, see: G. Hareau Vittini, P. J. Kocienski and G. Reid, *Synthesis*, 1995, 1007 1013.
37 G. Hareau Vittini and P. J. Kocienski, *Synlett*, 1995, 893 894.
38 (*a*) W. A. Slusarchyk, J. A. Osband and F. L. Weisenborn, *J. Am. Chem. Soc.*, 1970, **92**, 4486 4488; (*b*) W. A. Slusarchyk, J. A. Osband and F. L. Weisenborn, *Tetrahedron*, 1973, **29**, 1465 1472.
39 See ref. 17 and references cited therein.
40 P. A. Grieco, Y. Masaki and D. Boxler, *J. Org. Chem.*, 1975, **40**, 2261 2263.
41 (*a*) P. J. Kocienski and M. Todd, *J. Chem. Soc., Chem. Commun.*, 1982, 1078 1079; (*b*) P. J. Kocienski and M. Todd, *J. Chem. Soc., Perkin Trans. 1*, 1983, 1783 1789.
42 For the isolation of ceriferol and related sesterterpenoids, see: (*a*) F. Miyamoto, H. Naoki, T. Takemoto and Y. Naya, *Tetrahedron*, 1979, **35**, 1913 1917; (*b*) T. Kusumi, T. Kinoshita, K. Fujita and H. Kakisawa, *Chem. Lett.*, 1979, 1129 1132; (*c*) F. Miyamoto, H. Naoki, Y. Naya and K. Nakanishi, *Tetrahedron*, 1980, **36**, 3481 3487; (*d*) Y. Naya, F. Miyamoto, K. Kinoshita, T. Kusumi, H. Kakisawa and K. Nakanishi, *Chem. Lett.*, 1980, 883 886; (*e*) P. K. Pawlak, M. S. Tempest, T. Iwashita, K. Nakanishi and Y. Naya, *Chem. Lett.*, 1983, 1069 1072.
43 S. Fujiwara, M. Aoki, T. Uyehara and T. Kato, *Tetrahedron Lett.*, 1984, **25**, 3003 3006.
44 (*a*) M. Kodama, Y. Shiobara, H. Sumimoto, K. Fukuzumi, H. Minami and Y. Miyamoto, *Tetrahedron Lett.*, 1986, **27**, 2157 2160; (*b*) M. Kodama, Y. Shiobara, H. Sumitomo, K. Fukuzumi, H. Minami and Y. Miyamoto, *J. Org. Chem.*, 1988, **53**, 1437 1441.
45 Y. Ikeda, M. Aoki, T. Uyehara, T. Kato and T. Yokoyoma, *Chem. Lett.*, 1983, 1073 1076.
46 For the isolation and biological properties of terpestacin, see: (*a*) M. Oka, S. Iimura, O. Tenmyo, S. Yosuke, M. Sugawara, N. Okhusa, H. Yamamoto, K. Kawano, S. L. Hu, Y. Fukagawa and T. Oki, *J. Antibiot.*, 1993, **46**, 367 373; (*b*) S. Iimura, M. Osa, Y. Narita, M. Konishi, H. Kakisawa, Q. Gao and T. Oki, *Tetrahedron Lett.*, 1993, **34**, 493 496; (*c*) M. Oka, S. Iimura, Y. Narita, T. Furumai, M. Konishi, T. Oki, Q. Gao and H. Kakisawa, *J. Org. Chem.*, 1993, **58**, 1875 1881.
47 For synthetic studies toward terpestacin, see: (*a*) K. Takeda, A. Nakajima and E. Yoshii, *Synlett*, 1995, 249 250; (*b*) M. P. Mermet Mouttet, K. Gabriel and D. Heissler, *Tetrahedron Lett.*, 1999, **40**, 843 846.
48 T. J. Maimone and P. S. Baran, *Nat. Chem. Biol.*, 2007, **3**, 396 407.
49 K. Tatsuta, N. Masuda and H. Nishida, *Tetrahedron Lett.*, 1998, **39**, 83 86.
50 K. Tatsuta and N. Masuda, *J. Antibiot.*, 1998, **51**, 602 606.
51 A. G. Myers, M. Siu and F. Ren, *J. Am. Chem. Soc.*, 2002, **124**, 4230 4232.
52 (*a*) J. Chan and T. F. Jamison, *J. Am. Chem. Soc.*, 2003, **125**, 11514 11515; (*b*) J. Chan and T. F. Jamison, *J. Am. Chem. Soc.*, 2004, **126**, 10682 10691.
53 (*a*) B. M. Trost, G. Dong and J. A. Vance, *J. Am. Chem. Soc.*, 2007, **129**, 4540 4541; (*b*) B. M. Trost, G. Dong and J. A. Vance, *Chem. Eur. J.*, 2010, **16**, 6265 6277.
54 (*a*) G. O. Berger and M. A. Tius, *J. Org. Chem.*, 2007, **72**, 6473 6480; (*b*) for a previous communication dealing with the stereocontrolled synthesis of the cyclopentenone core structure of terpestacin, see: G. O. Berger and M. A. Tius, *Org. Lett.*, 2005, **7**, 5011 5013.
55 For the isolation and structural assignment of fusaproliferin, see: (*a*) G. Randazzo, V. Fogliano, A. Ritieni, L. Mannina, E. Rossi, A. Scarallo and A. L. Segre, *Tetrahedron*, 1993, **49**, 10883 10896; (*b*) C. Manetti, V. Fogliano, A. Ritieni, A. Santini, G. Randazzo, A. Logrieco, L. Mannina and A. L. Segre, *Struct. Chem.*, 1995, **6**, 183 189; (*c*) A. Santini, A. Ritieni, V. Fogliano, G. Randazzo, L. Mannina, A. Logrieco and E. Benedetti, *J. Nat. Prod.*, 1996, **59**, 109 112.
56 For the isolation and first biological activity tests of dysidiolide, see: G. P. Gunasekera, P. J. McCarthy, M. Kelly Borges, E. Lobkovsky and J. Clardy, *J. Am. Chem. Soc.*, 1996, **118**, 8759 8760.
57 For further biological studies on dysidiolide and structural analogues, see *e.g.*: (*a*) J. L. Blanchard, D. M. Espstein, M. D. Boisclair, J. Rudolph and K. Pal, *Bioorg. Med. Chem. Lett.*, 1999, **9**, 2537 2538; (*b*) M. Takahasi, K. Dodo, Y. Sugimoto, Y. Aoyagi, Y. Yamada, Y. Hashimoto and R. Shirai, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 2571 2574; (*c*) R. Shimazawa, T. Suzuki, K. Dodo and R. Shirai, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 3291 3294; (*d*) R. Shimazawa, M. Gochomori and R. Shirai, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 4339 4342.
58 E. J. Corey and B. E. Roberts, *J. Am. Chem. Soc.*, 1997, **119**, 12425 12431.
59 S. R. Magnuson, L. Sepp Lorenzino, N. Rosen and S. J. Danishefsky, *J. Am. Chem. Soc.*, 1998, **120**, 1615 1616.
60 D. Memeke and C. J. Forsyth, *Org. Lett.*, 2000, **2**, 3177 3179.
61 J. d'Angelo, D. Desmaele, F. Dumas and A. Guingant, *Tetrahedron: Asymmetry*, 1992, **3**, 459 505.
62 J. Boukouvalas, Y. X. Cheng and J. Robichaud, *J. Org. Chem.*, 1998, **63**, 228 229.
63 M. Takahashi, K. Dodo, Y. Hashimoto and R. Shirai, *Tetrahedron Lett.*, 2000, **41**, 2111 2114.
64 M. E. Jung and N. Nishimura, *Org. Lett.*, 2001, **3**, 2113 2115.
65 D. Brohm and H. Waldmann, *Tetrahedron Lett.*, 1998, **39**, 3995 3998.

66 (*a*) D. Brohm, S. Metzger, A. Bhargava, O. Muller, F. Lieb and H. Waldmann, *Angew. Chem., Int. Ed.*, 2002, **41**, 307 311; (*b*) D. Brohm, N. Philippe, S. Metzger, A. Bhargava, O. Muller, F. Lieb and H. Waldmann, *J. Am. Chem. Soc.*, 2002, **124**, 13171 13178.
67 H. Miyaoka, Y. Kajiwara and Y. Yamada, *Tetrahedron Lett.*, 2000, **41**, 911 914.
68 H. Miyaoka, Y. Kajiwara, Y. Hara and Y. Yamada, *J. Org. Chem.*, 2001, **66**, 1429 1435.
69 K. P. Kaliappan and P. Gowrisankar, *Tetrahedron Lett.*, 2004, **45**, 8207 8209.
70 E. Piers, S. Caillé and G. Chen, *Org. Lett.*, 2000, **2**, 2483 2486.
71 R. Paczkowski, C. Maichle Mossmer and M. E. Maier, *Org. Lett.*, 2000, **2**, 3967 3969.
72 A. Fontana, M. L. Ciavatta and G. Cimino, *J. Org. Chem.*, 1998, **63**, 2845 2849.
73 (*a*) I. S. Marcos, A. B. Pedrero, M. J. Sexmero, D. Díez, P. Basabe, F. A. Hernández, H. B. Broughton and J. G. Urones, *Synlett*, 2002, 105 109; (*b*) I. S. Marcos, A. B. Pedrero, M. J. Sexmero, D. Diez, P. Basabe, N. García, R. F. Moro, H. B. Broughton, F. Mollinedo and J. G. Urones, *J. Org. Chem.*, 2003, **68**, 7496 7504.
74 H. Miyaoka, M. Yamanishi and Y. Yamada, *J. Org. Chem.*, 2003, **68**, 3476 3479.
75 M. Nakagawa, Y. Ishihama, Y. Hamamoto and M. Endo, *Chem. Abstr.*, 1987, **106**, 96126b.
76 H. Hagiwara and H. Uda, *J. Chem. Soc., Perkin Trans. 1*, 1991, 1803 1807.
77 E. Piers and J. S. M. Wai, *J. Chem. Soc., Chem. Commun.*, 1987, 1342 1343.
78 B. Sullivan and D. J. Faulkner, *Tetrahedron Lett.*, 1982, **23**, 907 910.
79 A. K. Cheung and M. L. Snapper, *J. Am. Chem. Soc.*, 2002, **124**, 11584 11585.
80 (*a*) S. De Rosa, A. Crispino, A. De Giulio, C. Iodice, R. Pronzato and V. Zabodnik, *J. Nat. Prod.*, 1995, **58**, 1776 1780; (*b*) A. Soriente, A. Crispino, M. De Rosa, S. De Rosa, A. Scettri, G. Scognamiglio, R. Villano and G. Sodano, *Eur. J. Org. Chem.*, 2000, **2000**, 947 953.
81 P. Basabe, O. Boderam, I. S. Marcos, D. Díez, A. Blanco, M. De Román and J. C. Urones, *J. Org. Chem.*, 2009, **74**, 7750 7754.
82 B. C. M. Potes, R. J. Capon and D. J. Faulkner, *J. Org. Chem.*, 1992, **57**, 2965 2967.
83 W. Hofheinz and P. Schonholzer, *Helv. Chim. Acta*, 1977, **60**, 1367 1370.
84 R. P. Gregson and D. Ouvrier, *J. Nat. Prod.*, 1982, **45**, 412 414.
85 For a more detailed discussion on the synthesis of ircinianin as part of a review on synthetic strategies toward naturally occurring tetronic acids, see: A. L. Zografos and D. Georgiadis, *Synthesis*, 2006, 3157 3188.
86 K. Takeda, M. a. Sato and E. Yoshii, *Tetrahedron Lett.*, 1986, **27**, 3903 3906.
87 J. Uenishi, R. Kawahama and O. Yonemitsu, *J. Org. Chem.*, 1997, **62**, 1691 1701.
88 A. Fontana, I. Fakhr, E. Mollo and G. Cimino, *Tetrahedron: Asymmetry*, 1999, **10**, 3869 3872.
89 (*a*) S. H. Luo, Q. Luo, X. M. Niu, M. J. Xie, X. Zhao, B. Schneider, J. Gershenzon and S. H. Li, *Angew. Chem., Int. Ed.*, 2010, **49**, 4471 4475; (*b*) S. H. Luo, L. H. Weng, M. J. Xie, X. N. Li, J. Hua, X. Zhao and S. H. Li, *Org. Lett.*, 2011, **13**, 1864 1867.
90 J. Xie, Y. Ma and D. A. Horne, *J. Org. Chem.*, 2011, **76**, 6169 6176.
91 G. Brochere Ferreol and J. Polonsky, *Bull. Soc. Chim. Fr.*, 1960, 963 967.
92 For further structural assignment of gascardic acid, see: R. Scartazzini, Ph.D. Thesis, ETH Zurich, 1966.
93 For further synthetic approaches to install the carbon skeleton of gascardic acid, see: (*a*) U. Sanyal, P. K. Ghosal and P. C. Dutta, *Tetrahedron Lett.*, 1978, **19**, 2187 2190; (*b*) G. Bérubé and A. G. Fallis, *Tetrahedron Lett.*, 1989, **30**, 4045 4048; (*c*) G. Bérubé and A. G. Fallis, *Can. J. Chem.*, 1991, **69**, 77 83.
94 R. K. Boeckman, Jr., D. M. Blum and S. D. Arthur, *J. Am. Chem. Soc.*, 1979, **101**, 5060 5062.
95 R. K. Boeckman, Jr., D. M. Blum, E. V. Arnold and J. Clardy, *Tetrahedron Lett.*, 1979, **20**, 4609 4612.
96 For the isolation and structure determination of ophiobolin A, see: (*a*) K. Ishibashi and R. Nakamura, *J. Agric. Chem. Soc. Jpn.*, 1958, **32**, 739 744; (*b*) S. Nozoe, M. Morisaki, K. Tsuda, Y. Iitaka, N. Tokahashi, S. Tamura, K. Ishibashi and M. Shirasaka, *J. Am. Chem. Soc.*, 1965, **87**, 4968 4970.
97 For a review on the biology of ophiobolins, see: T. K. Au, W. S. H. Chick and P. C. Leung, *Life Sci.*, 2000, **67**, 733 742.
98 For synthetic studies toward the common carbon skeleton of the ophiobolins and ceroplastins, see: (*a*) W. G. Dauben and D. J. Hart, *J. Org. Chem.*, 1977, **42**, 922 923; (*b*) T. K. Das, P. C. Dutta, G. Kartha and J. M. Bernassau, *J. Chem. Soc., Perkin Trans. 1*, 1977, 1287 1295; (*c*) R. K. Boeckman, Jr., J. P. Bershas, J. Clardy and B. Solheim, *J. Org. Chem.*, 1977, **42**, 3630 3633; (*d*) L. A. Paquette, J. A. Colabret and D. R. Andrews, *J. Org. Chem.*, 1983, **48**, 1147 1149; (*e*) L. A. Paquette, J. A. Colabret and D. R. Andrews, *J. Org. Chem.*, 1985, **50**, 201 205; (*f*) R. M. Coates, J. W. Muskopf and P. A. Senter, *J. Org. Chem.*, 1985, **50**, 3541 3557; (*g*) G. Mehta and N. Krishnamurthy, *J. Chem. Soc., Chem. Commun.*, 1986, 1319 1321; (*h*) M. Umehara, S. Hishida, S. Okumoto, S. Ohba, M. Ito and S. Saito, *Bull. Chem. Soc. Jpn.*, 1987, **60**, 4474 4476; (*i*) J. H. Rigby and C. Senanayake, *J. Org. Chem.*, 1987, **52**, 4634 4635; (*j*) W. G. Dauben and A. M. Warshawsky, *J. Org. Chem.*, 1990, **55**, 3075 3087; (*k*) L. A. Paquette, S. Liang and P. Galatsis, *Synlett*, 1990, 663 665; (*l*) B. B. Snider and K. Yang, *J. Org. Chem.*, 1992, **57**, 3615 3626; (*m*) J. H. Rigby, T. McGuire, C. Senanayake and K. Khemani, *J. Chem. Soc., Perkin Trans. 1*, 1994, 3449 3457; (*n*) L. A. Paquette, S. Liang and H. L. Wang, *J. Org. Chem.*, 1996, **61**, 3268 3279; (*o*) A. J. Blake, A. J. Highton, T. N. Majid and N. S. Simpkins, *Org. Lett.*, 1999, **1**, 1787 1789; (*p*) K. F. McGee, Jr., T. H. Al Tel and S. M. Sieburth, *Synthesis*, 2001, 1185 1196; (*q*) P. C. K. Lo and M. L. Snapper, *Org. Lett.*, 2001, **3**, 2819 2821; (*r*) P. K. Ruprah, J. P. Cros, J. E. Pease, W. G. Whittingham and J. M. J. Williams, *Eur. J. Org. Chem.*, 2002, **2002**, 3145 3152; (*s*) B. Salem and J. Suffert, *Angew. Chem., Int. Ed.*, 2004, **43**, 2826 2830; (*t*) K. Michalak, M. Michalak and J. Wicha, *Molecules*, 2005, **10**, 1084 1100; (*u*) K. Michalak, M. Michalak and J. Wicha, *Tetrahedron Lett.*, 2005, **46**, 1149 1153; (*v*) C. Bour, G. Blond, B. Salem and J. Suffert, *Tetrahedron*, 2006, **62**, 10567 10581; (*w*) M. Michalak, K. Michalak, Z. Urbanczyk Lipkowska and J. Wicha, *J. Org. Chem.*, 2011, **76**, 7497 7509.
99 S. Nozoe, K. Hirai and K. Tsuda, *Tetrahedron Lett.*, 1966, **7**, 2211 2216.
100 M. Rowley, M. Tsukamoto and Y. Kishi, *J. Am. Chem. Soc.*, 1989, **111**, 2735 2737.
101 K. Tsuna, N. Noguchi and M. Nakada, *Angew. Chem., Int. Ed.*, 2011, **50**, 9452 9455.
102 For reviews on the synthesis of cyclooctanoid systems including discussions of the methods used within the synthesis of ophiobolin C, ceroplastol I and ceroplastol II as well as of some approaches toward the ophiobolin/ceroplastin skeleton, ref. 98, see: (*a*) G. Mehta and V. Singh, *Chem. Rev.*, 1999, **99**, 881 930; (*b*) N. A. Petasis and M. A. Patane, *Tetrahedron*, 1992, **48**, 5757 5821.
103 Kishi installed the two stereogenic centers within the first four steps of this sequence following a procedure described previously, see: J. H. Hutchinson, T. Money and S. E. Piper, *Can. J. Chem.*, 1986, **64**, 854 860.
104 For Kishi's successful synthesis of the building block **153** as well as the ophionbolin core lacking the side chain, see: M. Rowley and Y. Kishi, *Tetrahedron Lett.*, 1988, **29**, 4909 4912.
105 Nakada's asymmetric synthesis of the spirocyclic portion of ophiobolin A has been communicated previously, see: N. Noguchi and M. Nakada, *Org. Lett.*, 2006, **8**, 2039 2042.
106 In the communication of the disclosed synthesis, ref. 101, Nakada noted that carefully optimized, but not further specified reaction conditions increased the yield of this cyclization to 68%.
107 (*a*) T. Ríos and F. Colunga, *Chem. Ind. (London)*, 1965, 1184 1185; (*b*) Y. Itake, I. Watanabe, I. T. Harrison and S. Harrison, *J. Am. Chem. Soc.*, 1968, **90**, 1092 1093.
108 T. Ríos and L. Quijano, *Tetrahedron Lett.*, 1969, **10**, 1317 1318.
109 T. Ríos and F. Gómez, *Tetrahedron Lett.*, 1969, **10**, 2929 2930.
110 R. K. Boeckman, Jr., A. Arvantis and M. E. Voss, *J. Am. Chem. Soc.*, 1989, **111**, 2737 2739.
111 L. A. Paquette, T. Z. Wang and N. H. Vo, *J. Am. Chem. Soc.*, 1993, **115**, 1676 1683.

112 For Piers' useful protocol to conduct a methylenecyclopentane annulation by a cuprate addition/alkylation sequence, see: E. Piers and V. Karunaratne, *J. Chem. Soc., Chem. Commun.*, 1983, 935 936.

113 (*a*) N. Kato, H. Kataoka, S. Ohbuchi, S. Tanaka and H. Takeshita, *J. Chem. Soc., Chem. Commun.*, 1988, 354 356; (*b*) N. Kato, H. Takeshita, H. Kataoka, S. Ohbuchi and S. Tanaka, *J. Chem. Soc., Perkin Trans. 1*, 1989, 165 174.

114 For the preparation of building blocks as well as Kato's synthesis of the carbon skeleton of ceroplastol II, see: (*a*) H. Takeshita, T. Hatsui, N. Kato, T. Madsuda and T. Tagoshi, *Chem. Lett.*, 1982, 1153 1156; (*b*) N. Kato, S. Tanka and H. Takeshita, *Chem. Lett.*, 1986, 1989 1992; (*c*) N. Kato, K. Nakanishi and H. Takeshita, *Bull. Chem. Soc. Jpn.*, 1986, **59**, 1109 1123.

115 N. Ungur and V. Kulciţki, *Tetrahedron*, 2009, **65**, 3815 3828.

116 For the isolation of hyrtiosal, see: K. Iguchi, Y. Shimada and Y. Yamada, *J. Org. Chem.*, 1992, **57**, 522 524.

117 For syntheses of hyrtiosal, see: (*a*) P. Basabe, A. Diego, D. Díez, I. S. Marcos and J. G. Urones, *Synlett*, 2000, 1807 1809; (*b*) I. Lunardi, G. M. P. Santiago and P. Imamura, *Tetrahedron Lett.*, 2002, **43**, 3609 3611.

118 L. Ferreiro Mederos, S. Lanners, H. Henchiri, A. Fekih and G. Hanquet, *Nat. Prod. Res.*, 2009, **23**, 256 263.

119 A. Randazzo, C. Debitus, L. Minale, P. García Pastor, M. J. Alcaraz, M. Payá and L. Gomez Paloma, *J. Nat. Prod.*, 1998, **61**, 571 575.

120 N. Kawahara, M. Nozawa, A. Kurata, T. Hakamatsuka, S. Sekita and M. Satake, *Chem. Pharm. Bull.*, 1999, **47**, 1344 1345.

121 (*a*) M. S. Wilson and G. R. Dake, *Org. Lett.*, 2001, **3**, 2041 2044; (*b*) M. S. Wilson, J. C. S. Woo and G. R. Dake, *J. Org. Chem.*, 2006, **71**, 4237 4245.

122 M. S. Tempesta, Z. Iwashita, F. Miyamoto, K. Yoshihara and Y. Naya, *J. Chem. Soc., Chem. Commun.*, 1983, 1182 1183.

123 (*a*) M. A. Poupart and L. A. Paquette, *Tetrahedron Lett.*, 1988, **29**, 269 272; (*b*) L. A. Paquette and M. A. Poupart, *J. Org. Chem.*, 1993, **58**, 4245 4253; (*c*) L. A. Paquette, G. Y. Lasalle and C. J. Lovely, *J. Org. Chem.*, 1993, **58**, 4254 4261; (*d*) L. A. Paquette, D. N. Deaton, Y. Endo and M. A. Poupart, *J. Org. Chem.*, 1993, **58**, 4262 4273; (*e*) L. A. Paquette, S. Hormuth and C. J. Lovely, *J. Org. Chem.*, 1995, **60**, 4813 4821.

124 L. A. Paquette and B. Y. Dyck, *J. Am. Chem. Soc.*, 1998, **120**, 5953 5960.

125 For a recent review on isolated structures and biological properties of scalaranes, see: M. A. González, *Curr. Bioact. Compd.*, 2010, **6**, 178 206.

126 N. Ungur and V. Kulciţki, *Phytochem. Rev.*, 2004, **3**, 401 415.

127 For the synthesis of scalarolide, see: (*a*) X. J. Meng, Y. Liu, W. Y. Fan, B. Hu, W. Du and W. D. Deng, *Tetrahedron Lett.*, 2009, **50**, 4983 4985; (*b*) W. Y. Fan, Z. L. Wang, Z. G. Zhang, H. C. Li and W. P. Deng, *Tetrahedron*, 2011, **67**, 5596 5603.

128 For the isolation and biological properties of sestertatins, see: (*a*) G. R. Pettit, R. Tan, N. Melody, Z. A. Cichacz, D. L. Herald, M. S. Hoard, R. K. Pettit and J. C. Chapuis, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 2093 2098; (*b*) G. R. Pettit, R. Tan and Z. A. Cichacz, *J. Nat. Prod.*, 2005, **68**, 1253 1255.

129 For the synthesis of sestertatins 4 and 5, see: W. Y. Fan, Z. L. Wang, H. C. Li, J. S. Fossey and W. P. Deng, *Chem. Commun.*, 2011, **47**, 2961 2963.

130 For the isolation of 16 deacetoxy 12 *epi* scalarafuran acetate, see: A. De Giulio, S. De Rosa, G. Di Vincenzo and N. Zavodnik, *J. Nat. Prod.*, 1989, **52**, 1258 1262.

131 For syntheses of 16 deacetoxy 12 *epi* scalarafuran acetate, see: (*a*) X. B. Chen, Q. J. Yuan, J. Wang, S. K. Hua, J. Ren and B. B. Zeng, *J. Org. Chem.*, 2011, **76**, 7216 7221; (*b*) Z. L. Wang, Z. G. Zhang, H. C. Li and W. P. Deng, *Tetrahedron*, 2011, **67**, 6939 6964.

132 H. N. Kamel, Y. B. Kim, J. M. Rimoldi, F. R. Fronczek, D. Ferreira and M. Slattery, *J. Nat. Prod.*, 2009, **72**, 1492 1496.

133 (*a*) R. Kazlauskas, P. T. Murphy, R. Q. Quinn and R. J. Wells, *Tetrahedron Lett.*, 1976, **17**, 2631 2634; (*b*) Y. Kashman and A. Rudi, *Tetrahedron*, 1977, **33**, 2997 2998; (*c*) A. D. Patil, J. W. Westley, P. W. Baures and D. S. Eggleston, *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.*, 1991, **C47**, 1250 1253; (*d*) the absolute configuration of heteronemin as depicted in Scheme 24 is thus far only assigned tentatively as ( ) based on stereospecificity of biosynthetic pathways and comparison with related natural products, see: J. Anderson Clement, Ph.D. Thesis, Virginia Polytechnic Institute and State University, 2005.

134 E. Piers and S. L. Boulet, *Tetrahedron Lett.*, 1997, **38**, 8815 8818.

135 (*a*) O. D. Hensens, D. Zink, J. M. Williamson, V. J. Lotti, R. S. L. Chang and M. A. Goetz, *J. Org. Chem.*, 1991, **56**, 3399 3403; (*b*) H. Fujimoto, E. Nakamura, E. Okuyama and M. Ishibashi, *Chem. Pharm. Bull.*, 2000, **48**, 1436 1441.

136 S. D. Walker, Ph.D. thesis, University of British Columbia, 2002.

137 For the isolation of variecolol and variecolactone, see: H. Takahashi, T. Hosoe, K. Nozawa and K. Kawai, *J. Nat. Prod.*, 1999, **62**, 1712 1713.

138 G. A. Molander, M. S. Quirmbach, L. F. Silva, Jr., K. C. Spencer and J. Balsells, *Org. Lett.*, 2001, **3**, 2257 2260.

139 K. Araki, K. Saito, H. Arimoto and D. Uemura, *Angew. Chem., Int. Ed.*, 2004, **43**, 81 84.

140 For the isolation and biological properties of mangicols and neomangicols, see: (*a*) M. K. Renner, P. R. Jensen and W. Fenical, *J. Org. Chem.*, 1998, **63**, 8346 8354; (*b*) M. K. Renner, P. R. Jensen and W. Fenical, *J. Org. Chem.*, 2000, **65**, 4843 4852.

141 (*a*) S. Pichlmair, M. de Lera Ruiz, K. Basu and L. A. Paquette, *Tetrahedron*, 2006, **62**, 5178 5194; (*b*) S. Pichlmair, M. de Lera Ruiz, I. Vilotijevic and L. A. Paquette, *Tetrahedron*, 2006, **62**, 5791 5802.

142 J. L. Wood, B. G. Pujanauski and R. Sarpong, *Org. Lett.*, 2009, **11**, 3128 3131.

143 Y. Wang, M. Dreyfuss, M. Ponelle, L. Oberer and H. Riezman, *Tetrahedron*, 1998, **54**, 6415 6426.

144 R. Mizutani, K. Nakashima, Y. Saito, M. Sono and M. Tori, *Tetrahedron Lett.*, 2009, **50**, 2225 2227.

145 For isolation and structure determination of retigeranic acids, see: (*a*) P. S. Rao, K. G. Sarma and T. R. Seshadri, *Curr. Sci.*, 1965, **34**, 9 11; (*b*) M. Kaneda, R. Takahashi, Y. Iiataka and S. Shibata, *Tetrahedron Lett.*, 1972, **13**, 4609 4611; (*c*) M. Kaneda, R. Takahashi and S. Shibata, *Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem.*, 1974, **B30**, 358 364; (*d*) H. Sugawara, A. Kasuya, Y. Iitaka and S. Shibata, *Chem. Pharm. Bull.*, 1991, **39**, 3051 3054.

146 E. J. Corey, M. C. Desai and T. A. Engler, *J. Am. Chem. Soc.*, 1985, **107**, 4339 4341.

147 From here on we refer to retigeranic acid A as retigeranic acid.

148 For an excellent, detailed discussion on the syntheses of retigeranic acid, see: T. Hudlicky and J. W. Reed, *The Way of Synthesis: Evolution of Design and Methods for Natural Products*, Wiley VCH, Weinheim, 1st edn, 2007, page 392.

149 For a brief discussion on the syntheses of retigeranic acid as part of a review on polyquinanes, see: G. Mehta and A. Srikrishna, *Chem. Rev.*, 1997, **97**, 671 720.

150 (*a*) L. A. Paquette, J. Wright, G. J. Drtina and R. A. Roberts, *J. Org. Chem.*, 1987, **52**, 2960 2962; (*b*) J. Wright, G. J. Drtina, R. A. Roberts and L. A. Paquette, *J. Am. Chem. Soc.*, 1988, **110**, 5806 5817.

151 (*a*) T. Hudlicky, L. Radesca Kwart, L. q. Li and T. Bryant, *Tetrahedron Lett.*, 1988, **29**, 3283 3286; (*b*) T. Hudlicky, A. Fleming and L. Radesca, *J. Am. Chem. Soc.*, 1989, **111**, 6691 6707.

152 P. A. Wender and S. K. Singh, *Tetrahedron Lett.*, 1990, **31**, 2517 2520.

153 (*a*) B. B. Snider, D. J. Rodini and J. van Straten, *J. Am. Chem. Soc.*, 1980, **102**, 5872 5880; (*b*) E. J. Corey and T. A. Engler, *Tetrahedron Lett.*, 1984, **25**, 149 152.

154 For a review on the synthesis of *trans* hydrindane systems, see: P. Jankowski, S. Marzak and J. Wicha, *Tetrahedron*, 1998, **54**, 12071 12150.

155 For Paquette's previous communication on the synthesis of the triquinane portion, see: L. A. Paquette, R. A. Roberts and G. J. Drtina, *J. Am. Chem. Soc.*, 1984, **106**, 6690 6693.

156 This ring contraction has been described previously, see *e.g.*: J. N. Marx and L. R. Norman, *J. Org. Chem.*, 1975, **40**, 1602 1606.

157 Paquette's synthesis of alcohol 261 was optimized from a procedure reported by Newhall, see: W. R. Newhall, *J. Org. Chem.*, 1958, **23**, 1274 1276.

158 Hudlicky optimized a previously reported racemic synthesis of *trans* hydrindane 271, see: S. K. Attah Paku, F. Chau, V. K. Yadav and A. G. Fallis, *J. Org. Chem.*, 1985, **50**, 3418 3419.